{ "$schema_version": "5.3", "review_mode": "fresh", "claim_restatement": { "index_wording": "Neuroinflammation Hypothesis", "entry_form": "phenomenon", "gradeable_restatement": "Chronic microglial and astrocytic activation is a causal driver of neurodegeneration rather than a reactive response to it.", "restatement_required": true, "split_into": [], "parent_claim": null, "scope_qualifiers": [ { "qualifier": "Glial lineage and functional state, causal upstream insult, host genotype, disease subtype and stage, intervention target and timing", "determinable_before_outcome": true, "determined_from": "Enrollment and experimental design, before results; no responder-defined scope.", "action": "retained" } ] }, "hypothesis": { "name": "Neuroinflammation Hypothesis", "central_claim": "Chronic microglial and astrocytic activation is a causal driver of neurodegeneration rather than a reactive response to it.", "proposed_mechanism": "Chronic microglial and astrocytic activation is a causal driver of neurodegeneration rather than a reactive response to it.", "claimed_scope": "Chronic microglial and astrocytic activation is a causal driver of neurodegeneration rather than a reactive response to it.", "claimed_level": [ "progression" ], "is_conjunctive": true, "conjunctive_note": "Retain the original causal-driver-versus-reactive wording without silently adding an obligatory inflammation-first initiation claim. Presence, causal contribution, direction and cross-disease scope are scored separately. A downstream amplifier may be causal despite being reactive; this semantic distinction is explicit." }, "rubric_routing": { "primary_rubric": "01-neurodegeneration.md", "secondary_rubrics": [ "05-immunology-inflammation.md" ], "index_notes_applied": [ "Retain the original causal-driver-versus-reactive wording without silently adding an obligatory inflammation-first initiation claim. Presence, causal contribution, direction and cross-disease scope are scored separately. A downstream amplifier may be causal despite being reactive; this semantic distinction is explicit." ], "rubric_fit_note": "Exact archived v5.3 framework. Any stale index empirical framing is rechecked against primary results." }, "subclaim_matrix": { "subclaims": [ { "id": "SC1", "statement": "Glial activation is present in neurodegenerative disease and can precede overt neuronal loss.", "subclaim_type": "existence", "scope": "AD, PD and ALS with prespecified stage and cell type", "claimed_scope": "AD, PD and ALS with prespecified stage and cell type", "governing_rubric": "01-neurodegeneration.md", "key_evidence_anchor": "Longitudinal and presymptomatic tissue evidence", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Presymptomatic animal changes and human preclinical/longitudinal observations exceed terminal colocalization alone. Human state ordering and direct neuronal-loss mediation remain unresolved; pseudotime and structural equation modeling do not identify an initiating event." }, { "id": "SC2", "statement": "Specific chronic glial states contribute causally to neuronal loss and functional decline.", "subclaim_type": "mechanism", "scope": "defined cell states, genotypes, stages and disease models", "claimed_scope": "defined cell states, genotypes, stages and disease models", "governing_rubric": "01-neurodegeneration.md", "key_evidence_anchor": "Cell-selective perturbation with functional/neuronal endpoints and rescue", "hsef_level": "Ε", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Endogenous cell-lineage perturbations of mutant SOD1, NFκB and astrocytic APOE, as well as complementary immune manipulations, materially alter survival, atrophy or function in specified models. Defined mediator causality crosses Δ and merits Ε with explicit genotype, state and timing restrictions. Protective SYK, TREM2, IL3 and innate signaling states rule out indiscriminate activation suppression." }, { "id": "SC3", "statement": "Glial activation drives degeneration beyond a purely reactive or clearance response.", "subclaim_type": "primacy", "scope": "disease-relevant temporal and bidirectional perturbation settings", "claimed_scope": "disease-relevant temporal and bidirectional perturbation settings", "governing_rubric": "01-neurodegeneration.md", "key_evidence_anchor": "Early and late manipulations separating initiation from amplification and protection", "hsef_level": "Ε", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Glial contributions exceed a passive bystander or clearance-only account. SOD1 removal in glia and partial NFκB suppression slow later progression without changing onset; these are reactive causal amplification, which qualifies under the registered wording. Astrocyte and microglial effects are not interchangeable and do not establish obligatory upstream initiation. This defined causal contribution is Ε." }, { "id": "SC4", "statement": "The causal-driver claim generalizes across AD, PD and ALS.", "subclaim_type": "generalization", "scope": "disease-class human and model populations defined before outcomes", "claimed_scope": "disease-class human and model populations defined before outcomes", "governing_rubric": "01-neurodegeneration.md", "key_evidence_anchor": "Independent causal evidence and mapped protective/null contexts", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "AD, PD and ALS models show context-dependent causal immune effects, but human pathway engagement has not reliably produced sustained clinical benefit. AL002, NLY01, AZA-PD, ADAPT, NSAID treatment and minocycline test different, incompletely selective mechanisms. Protective and harmful states require prospective boundaries; the general disease-class claim remains Γ." } ], "aggregation_rule": "weakest-link", "aggregation_preregistered": true, "aggregation_rationale": "Retain the original causal-driver-versus-reactive wording without silently adding an obligatory inflammation-first initiation claim. Presence, causal contribution, direction and cross-disease scope are scored separately. A downstream amplifier may be causal despite being reactive; this semantic distinction is explicit.", "primary_subclaim_id": "SC3", "aggregation_derivation": "The registered weakest-link conjunction returns Γ because disease-class human generalization remains unresolved. Defined glial states have real causal effects on neuronal loss and progression, including reactive amplifiers. This evidence is not dismissed for being downstream. Opposite effects of protective immune programs and negative or harmful human interventions prevent treating chronic activation as one broadly pathogenic exposure. The limiting gate is generalization and state-specific human mediation, not an added obligation to initiate disease.", "aggregation_alternatives": { "weakest_link_would_return": "Γ", "primary_subclaim_would_return": "Ε", "scope_matched_would_return": "Ε", "note": "Separate narrow successes do not replace the preregistered gate." }, "index_rule_deviation": "" }, "competing_models": { "models_evaluated": [ { "rank_in_tournament": 1, "model_id": "M2", "is_nominal": false, "name": "Reactive but causal amplifier", "core_claim": "Defined glial states respond to proteinopathy and causally worsen subsequent degeneration.", "explains_what_nominal_does_not": "Defined glial states respond to proteinopathy and causally worsen subsequent degeneration.", "strongest_supporting_evidence": [ "SOD1 glial removal, NFκB suppression and cytokine deletion slow later progression; APOE4 and immune-hub perturbations protect tau models." ], "strongest_contradictory_evidence": [ "Shared mutant backgrounds, systemic effects and uncertain human mediation prevent broader unconditional claims." ], "hsef_level_for_this_model": "Ε", "rationale": "SOD1 glial removal, NFκB suppression and cytokine deletion slow later progression; APOE4 and immune-hub perturbations protect tau models. Shared mutant backgrounds, systemic effects and uncertain human mediation prevent broader unconditional claims." }, { "rank_in_tournament": 2, "model_id": "M3", "is_nominal": false, "name": "Protective clearance and immune failure", "core_claim": "Some activated states preserve tissue through clearance, containment and immune coordination.", "explains_what_nominal_does_not": "Some activated states preserve tissue through clearance, containment and immune coordination.", "strongest_supporting_evidence": [ "SYK, TREM2, IL3, TRIF and MyD88 contrasts show deterioration when protective responses are impaired." ], "strongest_contradictory_evidence": [ "The same receptor can have opposite effects with amyloid versus tau, APOE genotype or timing." ], "hsef_level_for_this_model": "Ε", "rationale": "SYK, TREM2, IL3, TRIF and MyD88 contrasts show deterioration when protective responses are impaired. The same receptor can have opposite effects with amyloid versus tau, APOE genotype or timing." }, { "rank_in_tournament": 3, "model_id": "M4", "is_nominal": false, "name": "Neuron-autonomous proteinopathy", "core_claim": "Intrinsic neuronal protein dysfunction initiates injury that glia then modify.", "explains_what_nominal_does_not": "Intrinsic neuronal protein dysfunction initiates injury that glia then modify.", "strongest_supporting_evidence": [ "Motor-neuron SOD1 controls onset/early progression whereas glial removal primarily changes later progression." ], "strongest_contradictory_evidence": [ "It does not explain all progression without glial contributions and is not a universal origin claim." ], "hsef_level_for_this_model": "Ε", "rationale": "Motor-neuron SOD1 controls onset/early progression whereas glial removal primarily changes later progression. It does not explain all progression without glial contributions and is not a universal origin claim." }, { "rank_in_tournament": 4, "model_id": "M5", "is_nominal": false, "name": "Peripheral immune contribution", "core_claim": "Adaptive and peripheral innate signals interact with glia and alter defined model trajectories.", "explains_what_nominal_does_not": "Adaptive and peripheral innate signals interact with glia and alter defined model trajectories.", "strongest_supporting_evidence": [ "T-cell depletion, IFNγ blockade, marrow MyD88 and immune-suppression contrasts affect atrophy or survival." ], "strongest_contradictory_evidence": [ "Systemic interventions and brief human immune-modulation signals do not isolate a universal mediator." ], "hsef_level_for_this_model": "Ε", "rationale": "T-cell depletion, IFNγ blockade, marrow MyD88 and immune-suppression contrasts affect atrophy or survival. Systemic interventions and brief human immune-modulation signals do not isolate a universal mediator." }, { "rank_in_tournament": 5, "model_id": "M1", "is_nominal": true, "name": "Primary chronic glial driver", "core_claim": "Chronic harmful glial activation broadly drives degeneration.", "explains_what_nominal_does_not": "Chronic harmful glial activation broadly drives degeneration.", "strongest_supporting_evidence": [ "Causal perturbations across model systems and human immune-risk genetics support disease-relevant participation." ], "strongest_contradictory_evidence": [ "Broad activation is heterogeneous; causal human generalization and selective state mediation are unresolved." ], "hsef_level_for_this_model": "Γ", "rationale": "Causal perturbations across model systems and human immune-risk genetics support disease-relevant participation. Broad activation is heterogeneous; causal human generalization and selective state mediation are unresolved." } ], "tournament_summary": "Descriptive comparison; does not modify the nominal score. Use post-onset cell-state-selective loss/rescue with the initiating neuronal lesion held comparable. Measure neuron survival and function as well as clearance and peripheral immunity. A reactive amplifier predicts progression change without obligatory onset prevention; a purely passive response predicts no such change.", "study_separating_rank1_from_rank2": "Use post-onset cell-state-selective loss/rescue with the initiating neuronal lesion held comparable. Measure neuron survival and function as well as clearance and peripheral immunity. A reactive amplifier predicts progression change without obligatory onset prevention; a purely passive response predicts no such change.", "nominal_wins_only_by_funding_artifact": false, "level_unchanged_by_tournament": true }, "evidence_inventory": [ { "n": 1, "pmid": "34919646", "title": "Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state.", "citation": "Smajić S, Prada-Medina CA, Landoulsi Z et al. Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state. Brain : a journal of neurology. 2022.", "doi": "10.1093/brain/awab446", "pmcid": "PMC9050543", "url": "https://pubmed.ncbi.nlm.nih.gov/34919646/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34919646/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID34919646", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Single-nucleus profiles of six PD and five control midbrains identified activated microglial and astrocytic states alongside a dysfunctional neuronal cluster.", "what_it_does_not_show": "Postmortem states and risk enrichment do not identify initiating direction or glial necessity; the central-mechanism language exceeds selective intervention.", "confounders_present": [ "Postmortem states and risk enrichment do not identify initiating direction or glial necessity; the central-mechanism language exceeds selective intervention." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 2, "pmid": "34262178", "title": "Astrocytic interleukin-3 programs microglia and limits Alzheimer's disease.", "citation": "McAlpine CS, Park J, Griciuc A et al. Astrocytic interleukin-3 programs microglia and limits Alzheimer's disease. Nature. 2021.", "doi": "10.1038/s41586-021-03734-6", "pmcid": "PMC8934148", "url": "https://pubmed.ncbi.nlm.nih.gov/34262178/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34262178/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID34262178", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "Astrocytic IL-3 programs microglial motility and aggregate clearance and restricts pathology and cognitive decline in tested AD models.", "what_it_does_not_show": "Protective activation contradicts treating activation as uniformly toxic; constitutive cytokine and model backgrounds limit natural human mediation.", "confounders_present": [ "Protective activation contradicts treating activation as uniformly toxic; constitutive cytokine and model backgrounds limit natural human mediation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 3, "pmid": "39402379", "title": "Integrated multimodal cell atlas of Alzheimer's disease.", "citation": "Gabitto MI, Travaglini KJ, Rachleff VM et al. Integrated multimodal cell atlas of Alzheimer's disease. Nature neuroscience. 2024.", "doi": "10.1038/s41593-024-01774-5", "pmcid": "PMC11614693", "url": "https://pubmed.ncbi.nlm.nih.gov/39402379/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39402379/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "UpdateOf: PMID37292694" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID39402379", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "An 84-donor multimodal atlas reconstructed an early phase with inflammatory glia and selective inhibitory-neuron loss before broader later neuronal loss.", "what_it_does_not_show": "Pseudoprogression is cross-sectional reconstructed time, not repeated donor observation; early glia already coexist with pathology and cell loss. UpdateOf is a preceding preprint.", "confounders_present": [ "Pseudoprogression is cross-sectional reconstructed time, not repeated donor observation; early glia already coexist with pathology and cell loss. UpdateOf is a preceding preprint." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 4, "pmid": "37029500", "title": "Parkin regulates microglial NLRP3 and represses neurodegeneration in Parkinson's disease.", "citation": "Yan YQ, Zheng R, Liu Y et al. Parkin regulates microglial NLRP3 and represses neurodegeneration in Parkinson's disease. Aging cell. 2023.", "doi": "10.1111/acel.13834", "pmcid": "PMC10265164", "url": "https://pubmed.ncbi.nlm.nih.gov/37029500/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37029500/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID37029500", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Parkin loss increased LPS-triggered microglial NLRP3 assembly, motor impairment and dopaminergic loss; Parkin overexpression and HSP90 inhibition interrogated NLRP3 degradation.", "what_it_does_not_show": "Global Parkin deletion, imposed systemic LPS and broad HSP90 effects do not isolate a microglial-only natural PD initiator.", "confounders_present": [ "Global Parkin deletion, imposed systemic LPS and broad HSP90 effects do not isolate a microglial-only natural PD initiator." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 5, "pmid": "39167665", "title": "Microglia-specific IL-10 gene delivery inhibits neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.", "citation": "Bido S, Nannoni M, Muggeo S et al. Microglia-specific IL-10 gene delivery inhibits neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease. Science translational medicine. 2024.", "doi": "10.1126/scitranslmed.adm8563", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39167665/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39167665/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID39167665", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "Microglia-specific IL-10 delivery protected dopaminergic neurons in SNCA-overexpressing mice while inducing an activated prophagocytic microglial state and lymphocyte regulation.", "what_it_does_not_show": "Activation remains present in a protective state; local cytokine effects extend beyond microglia, and imposed SNCA expression restricts scope.", "confounders_present": [ "Activation remains present in a protective state; local cytokine effects extend beyond microglia, and imposed SNCA expression restricts scope." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 6, "pmid": "29892066", "title": "Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease.", "citation": "Yun SP, Kam TI, Panicker N et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. Nature medicine. 2018.", "doi": "10.1038/s41591-018-0051-5", "pmcid": "PMC6039259", "url": "https://pubmed.ncbi.nlm.nih.gov/29892066/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29892066/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID29892066", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "NLY01 reduced dopaminergic loss and behavioral deficits after synuclein fibrils and prolonged survival in A53T mice, associated with reduced neurotoxic astrocyte conversion.", "what_it_does_not_show": "GLP1R agonism and forced/transgenic proteinopathy do not establish selective glial mediation or human efficacy; the clinical trial is assessed separately.", "confounders_present": [ "GLP1R agonism and forced/transgenic proteinopathy do not establish selective glial mediation or human efficacy; the clinical trial is assessed separately." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 7, "pmid": "30381407", "title": "Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice.", "citation": "Gordon R, Albornoz EA, Christie DC et al. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Science translational medicine. 2018.", "doi": "10.1126/scitranslmed.aah4066", "pmcid": "PMC6483075", "url": "https://pubmed.ncbi.nlm.nih.gov/30381407/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30381407/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID30381407", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "MCC950 inhibited NLRP3 activity and improved motor, dopamine-neuron and aggregate endpoints in several rodent PD models; degeneration itself could activate the pathway.", "what_it_does_not_show": "This supports an injury-triggered causal amplifier, not obligatory inflammation-first origin; drug/pathway and induced-model scope must be retained.", "confounders_present": [ "This supports an injury-triggered causal amplifier, not obligatory inflammation-first origin; drug/pathway and induced-model scope must be retained." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 8, "pmid": "37118504", "title": "Complement C1q-dependent excitatory and inhibitory synapse elimination by astrocytes and microglia in Alzheimer's disease mouse models.", "citation": "Dejanovic B, Wu T, Tsai MC et al. Complement C1q-dependent excitatory and inhibitory synapse elimination by astrocytes and microglia in Alzheimer's disease mouse models. Nature aging. 2022.", "doi": "10.1038/s43587-022-00281-1", "pmcid": "PMC10154216", "url": "https://pubmed.ncbi.nlm.nih.gov/37118504/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37118504/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID37118504", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "C1q deletion reduced microglial and astrocytic synapse engulfment and restored density in TauP301S; astrocytic engulfment compensated when Trem2-dependent microglial phagocytosis failed.", "what_it_does_not_show": "Synapse density is not total neuronal survival, and global complement deletion affects multiple functions and engineered backgrounds.", "confounders_present": [ "Synapse density is not total neuronal survival, and global complement deletion affects multiple functions and engineered backgrounds." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 9, "pmid": "17203472", "title": "Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration.", "citation": "Qin L, Wu X, Block ML et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 2007.", "doi": "10.1002/glia.20467", "pmcid": "PMC2871685", "url": "https://pubmed.ncbi.nlm.nih.gov/17203472/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/17203472/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID17203472", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "A single high-dose systemic LPS or TNF exposure caused sustained brain inflammation and delayed progressive TH-positive nigral-neuron loss, with TNF-receptor comparisons.", "what_it_does_not_show": "The imposed systemic inflammatory insult and receptor-wide deletion do not establish native chronic glial primacy; TH loss is not an audited all-neuron count.", "confounders_present": [ "The imposed systemic inflammatory insult and receptor-wide deletion do not establish native chronic glial primacy; TH loss is not an audited all-neuron count." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 10, "pmid": "33046546", "title": "Astrocytes Protect Human Dopaminergic Neurons from α-Synuclein Accumulation and Propagation.", "citation": "Tsunemi T, Ishiguro Y, Yoroisaka A et al. Astrocytes Protect Human Dopaminergic Neurons from α-Synuclein Accumulation and Propagation. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2020.", "doi": "10.1523/JNEUROSCI.0954-20.2020", "pmcid": "PMC7643299", "url": "https://pubmed.ncbi.nlm.nih.gov/33046546/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33046546/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID33046546", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "cell culture", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "Human iPSC astrocytes reduced neuronal synuclein accumulation and transfer through lysosomal clearance; ATP13A2-deficient astrocytes lost part of this protection.", "what_it_does_not_show": "Protective glial function is demonstrated in culture, not intact organismal progression or a general absence of harmful glial states.", "confounders_present": [ "Protective glial function is demonstrated in culture, not intact organismal progression or a general absence of harmful glial states." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 11, "pmid": "29624735", "title": "Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.", "citation": "Castro-Sánchez S, García-Yagüe ÁJ, López-Royo T et al. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease. Glia. 2018.", "doi": "10.1002/glia.23338", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/29624735/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29624735/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID29624735", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "Cx3cr1 deficiency worsened AAV-A53T synuclein inflammation and dopaminergic degeneration, while wild-type synuclein injury was similar across receptor genotypes.", "what_it_does_not_show": "Receptor loss can remove restraint rather than simply reduce activation; developmental and mutant-expression contexts limit broad extrapolation.", "confounders_present": [ "Receptor loss can remove restraint rather than simply reduce activation; developmental and mutant-expression contexts limit broad extrapolation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 12, "pmid": "27033548", "title": "Complement and microglia mediate early synapse loss in Alzheimer mouse models.", "citation": "Hong S, Beja-Glasser VF, Nfonoyim BM et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science (New York, N.Y.). 2016.", "doi": "10.1126/science.aad8373", "pmcid": "PMC5094372", "url": "https://pubmed.ncbi.nlm.nih.gov/27033548/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27033548/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID27033548", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "C1q, C3 and CR3 inhibition reduced early amyloid-associated synapse loss; C1q was required for oligomer-induced synaptic and LTP toxicity in the tested models.", "what_it_does_not_show": "Early means before overt plaques, not before all amyloid or neuronal stress; complementary pathway controls support conditional mediation without proving human initiation.", "confounders_present": [ "Early means before overt plaques, not before all amyloid or neuronal stress; complementary pathway controls support conditional mediation without proving human initiation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 13, "pmid": "28802038", "title": "TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease.", "citation": "Ulland TK, Song WM, Huang SC et al. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. Cell. 2017.", "doi": "10.1016/j.cell.2017.07.023", "pmcid": "PMC5573224", "url": "https://pubmed.ncbi.nlm.nih.gov/28802038/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28802038/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID28802038", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "TREM2 deficiency impaired microglial metabolism, and cyclocreatine restored plaque clustering while reducing adjacent neuronal dystrophy.", "what_it_does_not_show": "A protective energetic/clearance program can be activated; metabolic rescue is broader than a single inflammatory mediator and occurs in amyloid-model scope.", "confounders_present": [ "A protective energetic/clearance program can be activated; metabolic rescue is broader than a single inflammatory mediator and occurs in amyloid-model scope." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 14, "pmid": "36306735", "title": "TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways.", "citation": "Wang S, Sudan R, Peng V et al. TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways. Cell. 2022.", "doi": "10.1016/j.cell.2022.09.033", "pmcid": "PMC9625082", "url": "https://pubmed.ncbi.nlm.nih.gov/36306735/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36306735/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID36306735", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph0, 1:RESULTS:paragraph2, 1:RESULTS:paragraph3, 1:RESULTS:paragraph6, 1:RESULTS:paragraph14. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "Microglial SYK deficiency impaired plaque encasement and worsened pathology and behavior; CLEC7A activation rescued microglial activation in TREM2-R47H mice.", "what_it_does_not_show": "Different activated programmes have different effects; antibody rescue of activation is not independently established complete human clinical rescue. Original Results: inducible SYK deletion lowers plaque-associated microgliosis but increases Aβ, neuritic dystrophy and memory impairment. Monocytes recover after washout; border-associated macrophages retain partial deletion. Late deletion also impairs clustering. CLEC7A rescue restores uptake and plaque morphology, not demonstrated long-term behavioral rescue.", "confounders_present": [ "Different activated programmes have different effects; antibody rescue of activation is not independently established complete human clinical rescue. Original Results: inducible SYK deletion lowers plaque-associated microgliosis but increases Aβ, neuritic dystrophy and memory impairment. Monocytes recover after washout; border-associated macrophages retain partial deletion. Late deletion also impairs clustering. CLEC7A rescue restores uptake and plaque morphology, not demonstrated long-term behavioral rescue." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "5xFAD/TREM2 disease platform shared with multiple clearance studies." ] }, { "n": 15, "pmid": "37442133", "title": "TREM2 receptor protects against complement-mediated synaptic loss by binding to complement C1q during neurodegeneration.", "citation": "Zhong L, Sheng X, Wang W et al. TREM2 receptor protects against complement-mediated synaptic loss by binding to complement C1q during neurodegeneration. Immunity. 2023.", "doi": "10.1016/j.immuni.2023.06.016", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/37442133/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37442133/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID37442133", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "TREM2-C1q binding restrained complement activation; haploinsufficiency worsened synapse engulfment and a binding peptide rescued synaptic impairment in tested models.", "what_it_does_not_show": "Human tissue complex associations do not establish causal direction; complement-restraint protection is distinct from globally harmful activation.", "confounders_present": [ "Human tissue complex associations do not establish causal direction; complement-restraint protection is distinct from globally harmful activation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 16, "pmid": "36989373", "title": "The neuronal pentraxin Nptx2 regulates complement activity and restrains microglia-mediated synapse loss in neurodegeneration.", "citation": "Zhou J, Wade SD, Graykowski D et al. The neuronal pentraxin Nptx2 regulates complement activity and restrains microglia-mediated synapse loss in neurodegeneration. Science translational medicine. 2023.", "doi": "10.1126/scitranslmed.adf0141", "pmcid": "PMC10467038", "url": "https://pubmed.ncbi.nlm.nih.gov/36989373/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36989373/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID36989373", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Nptx2 loss increased C1q-dependent microglial synapse removal, while neuronal Nptx2 overexpression restrained complement and synapse loss in aged tau mice.", "what_it_does_not_show": "The initiating alteration is neuronal complement restraint and one rescue uses AAV overexpression; synapse preservation is not whole-disease neuronal survival.", "confounders_present": [ "The initiating alteration is neuronal complement restraint and one rescue uses AAV overexpression; synapse preservation is not whole-disease neuronal survival." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 17, "pmid": "25728668", "title": "TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model.", "citation": "Wang Y, Cella M, Mallinson K et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell. 2015.", "doi": "10.1016/j.cell.2015.01.049", "pmcid": "PMC4477963", "url": "https://pubmed.ncbi.nlm.nih.gov/25728668/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25728668/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID25728668", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "TREM2 loss impaired damage-lipid sensing, microglial plaque clustering and survival and increased amyloid accumulation in 5xFAD.", "what_it_does_not_show": "Protective immune responsiveness is demonstrated in an amyloid context; amyloid load alone does not establish cognitive/neuron-loss mediation or chronic-state universality.", "confounders_present": [ "Protective immune responsiveness is demonstrated in an amyloid context; amyloid load alone does not establish cognitive/neuron-loss mediation or chronic-state universality." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 18, "pmid": "31257024", "title": "LC3-Associated Endocytosis Facilitates β-Amyloid Clearance and Mitigates Neurodegeneration in Murine Alzheimer's Disease.", "citation": "Heckmann BL, Teubner BJW, Tummers B et al. LC3-Associated Endocytosis Facilitates β-Amyloid Clearance and Mitigates Neurodegeneration in Murine Alzheimer's Disease. Cell. 2019.", "doi": "10.1016/j.cell.2019.05.056", "pmcid": "PMC6689199", "url": "https://pubmed.ncbi.nlm.nih.gov/31257024/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31257024/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "ErratumIn: PMID33306957" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID31257024", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "Myeloid or microglial LANDO loss increased cytokines and neurotoxic amyloid, with accelerated degeneration, altered signaling and memory deficits.", "what_it_does_not_show": "Loss of aggregate clearance may precede harmful inflammation, so pure inflammatory primacy is not isolated; a linked correction remains qualified.", "confounders_present": [ "Loss of aggregate clearance may precede harmful inflammation, so pure inflammatory primacy is not isolated; a linked correction remains qualified." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 19, "pmid": "32544086", "title": "Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration.", "citation": "Gratuze M, Leyns CE, Sauerbeck AD et al. Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration. The Journal of clinical investigation. 2020.", "doi": "10.1172/JCI138179", "pmcid": "PMC7456230", "url": "https://pubmed.ncbi.nlm.nih.gov/32544086/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32544086/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID32544086", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Human TREM2-R47H in PS19 reduced microglial reactivity, synapse phagocytosis, atrophy and synapse loss versus the common variant.", "what_it_does_not_show": "An AD-risk allele is protective in this tau-only model, mapping upstream substrate/stage context rather than proving uniform effects in natural AD.", "confounders_present": [ "An AD-risk allele is protective in this tau-only model, mapping upstream substrate/stage context rather than proving uniform effects in natural AD." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 20, "pmid": "40792655", "title": "Anti-Neuroinflammatory and Anti-Inflammatory Effects of the NLRP3 Inhibitor NT-0796 in Subjects with Parkinson's Disease.", "citation": "Clarke N, Thornton P, Reader V et al. Anti-Neuroinflammatory and Anti-Inflammatory Effects of the NLRP3 Inhibitor NT-0796 in Subjects with Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society. 2025.", "doi": "10.1002/mds.30307", "pmcid": "PMC12553988", "url": "https://pubmed.ncbi.nlm.nih.gov/40792655/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40792655/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID40792655", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Open-label NT-0796 in ten PD participants for 28 days showed CSF exposure and reduced inflammatory markers, with four healthy volunteers also studied.", "what_it_does_not_show": "Short safety/pharmacokinetic biomarker engagement without randomized clinical trajectory is not disease modification or evidence of a glial initiating event.", "confounders_present": [ "Short safety/pharmacokinetic biomarker engagement without randomized clinical trajectory is not disease modification or evidence of a glial initiating event." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 21, "pmid": "17900537", "title": "Complement 3-deficient mice are not protected against MPTP-induced dopaminergic neurotoxicity.", "citation": "Liang Y, Li S, Guo Q et al. Complement 3-deficient mice are not protected against MPTP-induced dopaminergic neurotoxicity. Brain research. 2007.", "doi": "10.1016/j.brainres.2007.08.033", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/17900537/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/17900537/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "ErratumIn: PMID not supplied" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID17900537", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "null", "what_it_shows": "C3 deficiency did not preserve dopamine-neuron/fiber or dopamine-metabolite endpoints after acute or chronic MPTP exposure.", "what_it_does_not_show": "This null constrains complement C3 in a toxin context, not every immune mediator; the linked notice corrects an author name.", "confounders_present": [ "This null constrains complement C3 in a toxin context, not every immune mediator; the linked notice corrects an author name." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 22, "pmid": "35794654", "title": "Terminal complement pathway activation drives synaptic loss in Alzheimer's disease models.", "citation": "Carpanini SM, Torvell M, Bevan RJ et al. Terminal complement pathway activation drives synaptic loss in Alzheimer's disease models. Acta neuropathologica communications. 2022.", "doi": "10.1186/s40478-022-01404-w", "pmcid": "PMC9258209", "url": "https://pubmed.ncbi.nlm.nih.gov/35794654/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35794654/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID35794654", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "C7 antibody and C6 knockout reduced plaque-adjacent spine/synapse loss in two AD models, implicating terminal complement activity.", "what_it_does_not_show": "Synapse endpoints are not audited neuron-survival/function trajectories, and constitutive knockout or systemic antibody may affect other compartments.", "confounders_present": [ "Synapse endpoints are not audited neuron-survival/function trajectories, and constitutive knockout or systemic antibody may affect other compartments." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 23, "pmid": "34716339", "title": "Microglia-specific overexpression of α-synuclein leads to severe dopaminergic neurodegeneration by phagocytic exhaustion and oxidative toxicity.", "citation": "Bido S, Muggeo S, Massimino L et al. Microglia-specific overexpression of α-synuclein leads to severe dopaminergic neurodegeneration by phagocytic exhaustion and oxidative toxicity. Nature communications. 2021.", "doi": "10.1038/s41467-021-26519-x", "pmcid": "PMC8556263", "url": "https://pubmed.ncbi.nlm.nih.gov/34716339/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34716339/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "ErratumIn: PMID34916524" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID34716339", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Microglia-selective synuclein overexpression caused dopamine-neuron degeneration without neuronal synuclein aggregation, and oxidative/nitrosative inhibition attenuated damage.", "what_it_does_not_show": "A strong imposed glial sufficiency setting is not physiological endogenous primacy; peripheral recruitment and broad oxidative inhibition remain alternative mediators. Linked correction qualified.", "confounders_present": [ "A strong imposed glial sufficiency setting is not physiological endogenous primacy; peripheral recruitment and broad oxidative inhibition remain alternative mediators. Linked correction qualified." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 24, "pmid": "35394877", "title": "STING mediates neurodegeneration and neuroinflammation in nigrostriatal α-synucleinopathy.", "citation": "Hinkle JT, Patel J, Panicker N et al. STING mediates neurodegeneration and neuroinflammation in nigrostriatal α-synucleinopathy. Proceedings of the National Academy of Sciences of the United States of America. 2022.", "doi": "10.1073/pnas.2118819119", "pmcid": "PMC9169780", "url": "https://pubmed.ncbi.nlm.nih.gov/35394877/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35394877/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID35394877", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "STING activation preceded dopamine-neuron loss after synuclein fibrils; STING-deficient mice resisted motor, aggregate and neuronal-loss phenotypes.", "what_it_does_not_show": "Global STING deficiency and imposed fibrils constrain cell specificity and natural initiation; human staining is correlational.", "confounders_present": [ "Global STING deficiency and imposed fibrils constrain cell specificity and natural initiation; human staining is correlational." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 25, "pmid": "33831349", "title": "Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia.", "citation": "Wang C, Xiong M, Gratuze M et al. Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. Neuron. 2021.", "doi": "10.1016/j.neuron.2021.03.024", "pmcid": "PMC8141024", "url": "https://pubmed.ncbi.nlm.nih.gov/33831349/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33831349/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID33831349", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph0, 1:RESULTS:paragraph1, 1:RESULTS:paragraph2, 1:RESULTS:paragraph15. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Inducible astrocytic APOE4 removal after tau pathology onset reduced neurodegeneration, synapse loss and microglial synaptic phagocytosis.", "what_it_does_not_show": "Post-onset protection supports causal amplification; APOE affects lipid and tau pathways in addition to inflammation, and the P301S/APOE context remains explicit. Original Results: astrocytic APOE deletion at 5.5 months after initial tau pathology protects APOE4 but not APOE3 mice from atrophy. Tamoxifen-treated Cre-negative controls exclude tamoxifen alone; NfL, nest building and synaptic measures improve. APOE influences lipid handling and tau pathology as well as inflammatory states, so the mediation is not inflammation-selective.", "confounders_present": [ "Post-onset protection supports causal amplification; APOE affects lipid and tau pathways in addition to inflammation, and the P301S/APOE context remains explicit. Original Results: astrocytic APOE deletion at 5.5 months after initial tau pathology protects APOE4 but not APOE3 mice from atrophy. Tamoxifen-treated Cre-negative controls exclude tamoxifen alone; NfL, nest building and synaptic measures improve. APOE influences lipid handling and tau pathology as well as inflammatory states, so the mediation is not inflammation-selective." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 26, "pmid": "29178139", "title": "Phagocytic clearance of presynaptic dystrophies by reactive astrocytes in Alzheimer's disease.", "citation": "Gomez-Arboledas A, Davila JC, Sanchez-Mejias E et al. Phagocytic clearance of presynaptic dystrophies by reactive astrocytes in Alzheimer's disease. Glia. 2018.", "doi": "10.1002/glia.23270", "pmcid": "PMC5814816", "url": "https://pubmed.ncbi.nlm.nih.gov/29178139/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29178139/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID29178139", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Microscopy in APP/PS1 and human AD tissue showed reactive astrocytes engulfing presynaptic dystrophies, with a low fraction of total dystrophies cleared.", "what_it_does_not_show": "Reactive phagocytosis may clear damage rather than kill viable synapses; proposed protection is not tested by this static study.", "confounders_present": [ "Reactive phagocytosis may clear damage rather than kill viable synapses; proposed protection is not tested by this static study." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 27, "pmid": "30734229", "title": "Microglial Depletion with Clodronate Liposomes Increases Proinflammatory Cytokine Levels, Induces Astrocyte Activation, and Damages Blood Vessel Integrity.", "citation": "Han X, Li Q, Lan X et al. Microglial Depletion with Clodronate Liposomes Increases Proinflammatory Cytokine Levels, Induces Astrocyte Activation, and Damages Blood Vessel Integrity. Molecular neurobiology. 2019.", "doi": "10.1007/s12035-019-1502-9", "pmcid": "PMC6684378", "url": "https://pubmed.ncbi.nlm.nih.gov/30734229/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30734229/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID30734229", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "Intracerebral clodronate depleted microglia but also damaged vascular integrity, reduced neural markers and increased inflammatory/glial signals; neuronal ATP fell in culture.", "what_it_does_not_show": "This methodological perturbation exposes depletion off-target confounding, rather than showing that all microglia protect in AD, PD or ALS.", "confounders_present": [ "This methodological perturbation exposes depletion off-target confounding, rather than showing that all microglia protect in AD, PD or ALS." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 28, "pmid": "28099414", "title": "Neurotoxic reactive astrocytes are induced by activated microglia.", "citation": "Liddelow SA, Guttenplan KA, Clarke LE et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017.", "doi": "10.1038/nature21029", "pmcid": "PMC5404890", "url": "https://pubmed.ncbi.nlm.nih.gov/28099414/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28099414/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID28099414", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Microglial IL1a, TNF and C1q induced toxic reactive astrocytes; blocking formation protected axotomized neurons, and human disease tissue contained the state.", "what_it_does_not_show": "Injury precedes the causal astrocyte response in the in-vivo test; human postmortem abundance and a marker class do not establish obligatory inflammation-first disease origin.", "confounders_present": [ "Injury precedes the causal astrocyte response in the in-vivo test; human postmortem abundance and a marker class do not establish obligatory inflammation-first disease origin." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 29, "pmid": "28602351", "title": "A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease.", "citation": "Keren-Shaul H, Spinrad A, Weiner A et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. Cell. 2017.", "doi": "10.1016/j.cell.2017.05.018", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/28602351/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28602351/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID28602351", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "Single-cell mapping and Trem2 loss separated two disease-associated microglial activation phases, with intracellular amyloid in mapped cells.", "what_it_does_not_show": "Potential protective function is not a selective hard-outcome rescue in this abstract; the DAM name is not a causal toxicity classification.", "confounders_present": [ "Potential protective function is not a selective hard-outcome rescue in this abstract; the DAM name is not a causal toxicity classification." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 30, "pmid": "39059388", "title": "Microglia rescue neurons from aggregate-induced neuronal dysfunction and death through tunneling nanotubes.", "citation": "Scheiblich H, Eikens F, Wischhof L et al. Microglia rescue neurons from aggregate-induced neuronal dysfunction and death through tunneling nanotubes. Neuron. 2024.", "doi": "10.1016/j.neuron.2024.06.029", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39059388/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39059388/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID39059388", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "cell culture", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "Microglial nanotube contacts removed neuronal tau/synuclein aggregates, supplied healthy mitochondria and restored activity; mitochondrial poisoning removed protection.", "what_it_does_not_show": "Broad mitochondrial perturbation and culture-based transfer do not establish organismal disease trajectory; aggregate transfer can be protective rather than uniformly toxic.", "confounders_present": [ "Broad mitochondrial perturbation and culture-based transfer do not establish organismal disease trajectory; aggregate transfer can be protective rather than uniformly toxic." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 31, "pmid": "31748742", "title": "NLRP3 inflammasome activation drives tau pathology.", "citation": "Ising C, Venegas C, Zhang S et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019.", "doi": "10.1038/s41586-019-1769-z", "pmcid": "PMC7324015", "url": "https://pubmed.ncbi.nlm.nih.gov/31748742/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31748742/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID31748742", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "NLRP3 loss reduced tau phosphorylation/aggregation, and amyloid-homogenate-induced tau pathology depended on NLRP3; tau itself activated the inflammasome.", "what_it_does_not_show": "The test supports a bidirectional proteinopathy-immune pathway, with imposed initiation and pathology endpoints rather than a complete human survival dependency.", "confounders_present": [ "The test supports a bidirectional proteinopathy-immune pathway, with imposed initiation and pathology endpoints rather than a complete human survival dependency." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 32, "pmid": "40747577", "title": "Early microglial and astrocyte reactivity in preclinical Alzheimer's disease.", "citation": "Fernández-Matarrubia M, Valera-Barrero A, Renuncio-García M et al. Early microglial and astrocyte reactivity in preclinical Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025.", "doi": "10.1002/alz.70502", "pmcid": "PMC12314543", "url": "https://pubmed.ncbi.nlm.nih.gov/40747577/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40747577/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID40747577", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "In 211 cognitively unimpaired people, glial fluid markers were elevated in preclinical AD and structural-equation relations linked them with amyloid, tau and injury markers.", "what_it_does_not_show": "Statistical arrows and biomarker mediation do not establish causal intervention or true temporal lineage; normal cognition does not mean absence of primary protein pathology.", "confounders_present": [ "Statistical arrows and biomarker mediation do not establish causal intervention or true temporal lineage; normal cognition does not mean absence of primary protein pathology." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 33, "pmid": "34825707", "title": "Microglial PD-1 stimulation by astrocytic PD-L1 suppresses neuroinflammation and Alzheimer's disease pathology.", "citation": "Kummer MP, Ising C, Kummer C et al. Microglial PD-1 stimulation by astrocytic PD-L1 suppresses neuroinflammation and Alzheimer's disease pathology. The EMBO journal. 2021.", "doi": "10.15252/embj.2021108662", "pmcid": "PMC8672180", "url": "https://pubmed.ncbi.nlm.nih.gov/34825707/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34825707/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID34825707", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "Microglial PD1 deletion increased inflammation and impaired amyloid uptake, with more plaque deposition in APP/PS1.", "what_it_does_not_show": "Loss of immune restraint and clearance is harmful in this context; plaque load is not independently demonstrated neuron loss or general inflammatory primacy.", "confounders_present": [ "Loss of immune restraint and clearance is harmful in this context; plaque load is not independently demonstrated neuron loss or general inflammatory primacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 34, "pmid": "29293211", "title": "Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer's disease.", "citation": "Venegas C, Kumar S, Franklin BS et al. Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer's disease. Nature. 2017.", "doi": "10.1038/nature25158", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/29293211/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29293211/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID29293211", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "ASC specks promoted amyloid cross-seeding after hippocampal delivery, and ASC deficiency or antibody coapplication blocked induced pathology.", "what_it_does_not_show": "Forced amyloid/speck entry and aggregate endpoints establish inflammatory seeding capability, not native disease initiation or clinical benefit.", "confounders_present": [ "Forced amyloid/speck entry and aggregate endpoints establish inflammatory seeding capability, not native disease initiation or clinical benefit." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 35, "pmid": "32579671", "title": "Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model.", "citation": "Wang S, Mustafa M, Yuede CM et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model. The Journal of experimental medicine. 2020.", "doi": "10.1084/jem.20200785", "pmcid": "PMC7478730", "url": "https://pubmed.ncbi.nlm.nih.gov/32579671/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32579671/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID32579671", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "AL002c stimulated microglial proliferation and reduced filamentous plaques and neurite dystrophy in a human-TREM2 AD model; first-human fluid engagement was also reported.", "what_it_does_not_show": "Activation can be protective in this model, and phase1 engagement is not human clinical efficacy; later reports overlap the clinical programme.", "confounders_present": [ "Activation can be protective in this model, and phase1 engagement is not human clinical efficacy; later reports overlap the clinical programme." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 36, "pmid": "36368315", "title": "TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4.", "citation": "Gratuze M, Schlachetzki JCM, D'Oliveira Albanus R et al. TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4. Neuron. 2023.", "doi": "10.1016/j.neuron.2022.10.022", "pmcid": "PMC9852006", "url": "https://pubmed.ncbi.nlm.nih.gov/36368315/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36368315/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID36368315", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "TREM2 knockout worsened tau pathology and degeneration in P301S/APOE4 despite reduced TREM2-dependent microgliosis.", "what_it_does_not_show": "This reverses the earlier mouse-Apoe tau-only protection contrast, showing genotype and residual microglial state matter more than bulk activation reduction.", "confounders_present": [ "This reverses the earlier mouse-Apoe tau-only protection contrast, showing genotype and residual microglial state matter more than bulk activation reduction." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 37, "pmid": "39444037", "title": "Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease.", "citation": "Long H, Simmons A, Mayorga A et al. Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease. Alzheimer's research & therapy. 2024.", "doi": "10.1186/s13195-024-01599-1", "pmcid": "PMC11515656", "url": "https://pubmed.ncbi.nlm.nih.gov/39444037/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39444037/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID39444037", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "INVOKE1 in 64 healthy volunteers showed AL002 CSF penetration, soluble-TREM2 reduction and signaling/recruitment biomarker increases with acceptable single-dose tolerability.", "what_it_does_not_show": "Healthy phase1 safety and engagement cannot establish AD trajectory benefit; the 2020 programme report is not independent efficacy evidence.", "confounders_present": [ "Healthy phase1 safety and engagement cannot establish AD trajectory benefit; the 2020 programme report is not independent efficacy evidence." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 38, "pmid": "32917267", "title": "The Alzheimer's disease-associated protective Plcγ2-P522R variant promotes immune functions.", "citation": "Takalo M, Wittrahm R, Wefers B et al. The Alzheimer's disease-associated protective Plcγ2-P522R variant promotes immune functions. Molecular neurodegeneration. 2020.", "doi": "10.1186/s13024-020-00402-7", "pmcid": "PMC7488484", "url": "https://pubmed.ncbi.nlm.nih.gov/32917267/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32917267/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID32917267", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "The AD-protective PLCG2-P522R knock-in increased enzyme activity, macrophage survival/acute responses and measures of microglial function.", "what_it_does_not_show": "Protective genetic association is from a separate study; cell function and PET signals do not prove chronic harmful activation or disease rescue in this KI experiment.", "confounders_present": [ "Protective genetic association is from a separate study; cell function and PET signals do not prove chronic harmful activation or disease rescue in this KI experiment." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 39, "pmid": "17980667", "title": "Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.", "citation": "Gordon PH, Moore DH, Miller RG et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. The Lancet. Neurology. 2007.", "doi": "10.1016/S1474-4422(07)70270-3", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/17980667/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/17980667/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID17980667", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "opposes", "what_it_shows": "In 412 randomized ALS patients, minocycline accelerated the prespecified ALSFRS-R decline compared with placebo over nine months.", "what_it_does_not_show": "Broad drug pharmacology and unverified selective glial engagement mean this refutes the tested treatment expectation, not all inflammatory causal contribution; mortality worsening was nonsignificant.", "confounders_present": [ "Broad drug pharmacology and unverified selective glial engagement mean this refutes the tested treatment expectation, not all inflammatory causal contribution; mortality worsening was nonsignificant." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 40, "pmid": "41787076", "title": "The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial.", "citation": "Mummery CJ, Mayorga AJ, Simmons A et al. The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial. Nature medicine. 2026.", "doi": "10.1038/s41591-026-04273-1", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/41787076/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41787076/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID41787076", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "INVOKE2 randomized 381 early-AD participants and found no CDR-SB benefit despite sustained central TREM2 engagement/signaling biomarkers; ARIA-like MRI events were prominent.", "what_it_does_not_show": "TREM2 agonism in symptomatic AD is a specific strategy; fluid engagement does not prove adequate state-specific glial rescue, and a clinical null does not eliminate all immune causality.", "confounders_present": [ "TREM2 agonism in symptomatic AD is a specific strategy; fluid engagement does not prove adequate state-specific glial rescue, and a clinical null does not eliminate all immune causality." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 41, "pmid": "41865758", "title": "Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.", "citation": "Cummings JL, Atri A, Sano M et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet (London, England). 2026.", "doi": "10.1016/S0140-6736(26)00459-9", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/41865758/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41865758/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "EVOKE-and-EVOKEplus-two-trials-one-report", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "Two phase3 semaglutide trials randomized 3808 early-AD participants and showed no slowing of 104-week CDR-SB progression.", "what_it_does_not_show": "GLP1R agonism is systemic and pleiotropic, without verified selective glial engagement here; this constrains broad drug translation rather than isolating a glial mechanism.", "confounders_present": [ "GLP1R agonism is systemic and pleiotropic, without verified selective glial engagement here; this constrains broad drug translation rather than isolating a glial mechanism." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Two randomized trials are contained in one examined report; GLP1 is pleiotropic, not an isolated glial test." ] }, { "n": 42, "pmid": "38101901", "title": "Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.", "citation": "McGarry A, Rosanbalm S, Leinonen M et al. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial. The Lancet. Neurology. 2024.", "doi": "10.1016/S1474-4422(23)00378-2", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/38101901/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38101901/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID38101901", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "NLY01 randomized 255 early untreated PD participants and showed no 36-week motor/ADL primary endpoint benefit at either dose, with frequent gastrointestinal events.", "what_it_does_not_show": "Exploratory younger-patient signals are not confirmatory; human microglial-state inhibition was not verified by this abstract, so null treatment efficacy is not complete mediator removal.", "confounders_present": [ "Exploratory younger-patient signals are not confirmatory; human microglial-state inhibition was not verified by this abstract, so null treatment efficacy is not complete mediator removal." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 43, "pmid": "41389828", "title": "Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial.", "citation": "Greenland JC, Dresser K, Cutting E et al. Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. The Lancet. Neurology. 2026.", "doi": "10.1016/S1474-4422(25)00386-2", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/41389828/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41389828/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID41389828", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "AZA-PD randomized 66 early PD participants and did not improve the prespecified 12-month off-state gait-axial endpoint; exploratory immune and sex-specific findings were reported.", "what_it_does_not_show": "Peripheral broad immunosuppression is not cell-state-selective glial blockade, and subgroup signals require replication; clinical null constrains the tested strategy.", "confounders_present": [ "Peripheral broad immunosuppression is not cell-state-selective glial blockade, and subgroup signals require replication; clinical null constrains the tested strategy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 44, "pmid": "28649610", "title": "Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial.", "citation": "Gendelman HE, Zhang Y, Santamaria P et al. Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial. NPJ Parkinson's disease. 2017.", "doi": "10.1038/s41531-017-0013-5", "pmcid": "PMC5445595", "url": "https://pubmed.ncbi.nlm.nih.gov/28649610/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28649610/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID28649610", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "A 20-person randomized PD phase1 study reported modest short-term motor improvement with sargramostim, peripheral Treg changes and substantial adverse-event burden.", "what_it_does_not_show": "Safety-focused small enrollment, short exposure and peripheral modulation do not establish sustained neuroprotection or prove a CNS glial mediator.", "confounders_present": [ "Safety-focused small enrollment, short exposure and peripheral modulation do not establish sustained neuroprotection or prove a CNS glial mediator." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 45, "pmid": "30635357", "title": "Heterozygous Tbk1 loss has opposing effects in early and late stages of ALS in mice.", "citation": "Brenner D, Sieverding K, Bruno C et al. Heterozygous Tbk1 loss has opposing effects in early and late stages of ALS in mice. The Journal of experimental medicine. 2019.", "doi": "10.1084/jem.20180729", "pmcid": "PMC6363427", "url": "https://pubmed.ncbi.nlm.nih.gov/30635357/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30635357/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID30635357", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "Heterozygous TBK1 loss advanced SOD1 onset/denervation but reduced late microglial inflammation, slowed progression and extended survival.", "what_it_does_not_show": "Global pleiotropic autophagy/immune effects show stage-dependent direction, rather than a universal beneficial inflammatory suppression or native sporadic ALS cause.", "confounders_present": [ "Global pleiotropic autophagy/immune effects show stage-dependent direction, rather than a universal beneficial inflammatory suppression or native sporadic ALS cause." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 46, "pmid": "25384799", "title": "System xC- is a mediator of microglial function and its deletion slows symptoms in amyotrophic lateral sclerosis mice.", "citation": "Mesci P, Zaïdi S, Lobsiger CS et al. System xC- is a mediator of microglial function and its deletion slows symptoms in amyotrophic lateral sclerosis mice. Brain : a journal of neurology. 2015.", "doi": "10.1093/brain/awu312", "pmcid": "PMC4441079", "url": "https://pubmed.ncbi.nlm.nih.gov/25384799/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25384799/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID25384799", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "xCT deletion reduced microglial glutamate and inflammatory outputs and slowed late SOD1 degeneration with more surviving motor neurons, despite earlier symptom onset.", "what_it_does_not_show": "Global antiporter deletion and redox effects complicate microglial specificity; onset and progression move in opposite directions.", "confounders_present": [ "Global antiporter deletion and redox effects complicate microglial specificity; onset and progression move in opposite directions." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 47, "pmid": "24170856", "title": "C1q induction and global complement pathway activation do not contribute to ALS toxicity in mutant SOD1 mice.", "citation": "Lobsiger CS, Boillée S, Pozniak C et al. C1q induction and global complement pathway activation do not contribute to ALS toxicity in mutant SOD1 mice. Proceedings of the National Academy of Sciences of the United States of America. 2013.", "doi": "10.1073/pnas.1318309110", "pmcid": "PMC3831990", "url": "https://pubmed.ncbi.nlm.nih.gov/24170856/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/24170856/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID24170856", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "null", "what_it_shows": "C1q or C3 loss did not change SOD1 disease onset/progression; C1q deletion enhanced rather than prevented loss of certain motor-neuron synaptic inputs.", "what_it_does_not_show": "Complement activation can be a correlate without disease-course necessity in this setting; null single mediators do not disprove all glial contributions.", "confounders_present": [ "Complement activation can be a correlate without disease-course necessity in this setting; null single mediators do not disprove all glial contributions." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 48, "pmid": "18246065", "title": "Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis.", "citation": "Yamanaka K, Chun SJ, Boillee S et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nature neuroscience. 2008.", "doi": "10.1038/nn2047", "pmcid": "PMC3137510", "url": "https://pubmed.ncbi.nlm.nih.gov/18246065/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/18246065/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID18246065", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Conditional mutant-SOD1 reduction in astrocytes left onset unchanged but delayed microglial activation and sharply slowed later progression.", "what_it_does_not_show": "This is direct cell-resolved causal amplification in familial SOD1 models, not proof of inflammation-first initiation or every reactive astrocyte being toxic.", "confounders_present": [ "This is direct cell-resolved causal amplification in familial SOD1 models, not proof of inflammation-first initiation or every reactive astrocyte being toxic." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 49, "pmid": "16741123", "title": "Onset and progression in inherited ALS determined by motor neurons and microglia.", "citation": "Boillée S, Yamanaka K, Lobsiger CS et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science (New York, N.Y.). 2006.", "doi": "10.1126/science.1123511", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/16741123/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/16741123/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID16741123", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Cell-resolved mutant-SOD1 deletion separated motor-neuron-determined onset/early progression from microglial effects on late progression.", "what_it_does_not_show": "Different disease phases and engineered familial mutation define scope; reducing mutant protein may restore several glial functions beyond inflammation.", "confounders_present": [ "Different disease phases and engineered familial mutation define scope; reducing mutant protein may restore several glial functions beyond inflammation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 50, "pmid": "25892237", "title": "Astrocyte-derived TGF-β1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells.", "citation": "Endo F, Komine O, Fujimori-Tonou N et al. Astrocyte-derived TGF-β1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells. Cell reports. 2015.", "doi": "10.1016/j.celrep.2015.03.053", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/25892237/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25892237/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID25892237", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "Astrocytic TGFβ1 overproduction worsened SOD1 progression while deactivating protective microglia/T cells; post-onset signaling inhibition extended survival.", "what_it_does_not_show": "Reducing one cytokine can improve protective immune activity rather than uniformly suppress activation; source overproduction and drug pleiotropy remain limits.", "confounders_present": [ "Reducing one cytokine can improve protective immune activity rather than uniformly suppress activation; source overproduction and drug pleiotropy remain limits." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 51, "pmid": "29568058", "title": "Innate immune adaptor TRIF deficiency accelerates disease progression of ALS mice with accumulation of aberrantly activated astrocytes.", "citation": "Komine O, Yamashita H, Fujimori-Tonou N et al. Innate immune adaptor TRIF deficiency accelerates disease progression of ALS mice with accumulation of aberrantly activated astrocytes. Cell death and differentiation. 2018.", "doi": "10.1038/s41418-018-0098-3", "pmcid": "PMC6261996", "url": "https://pubmed.ncbi.nlm.nih.gov/29568058/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29568058/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID29568058", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "TRIF deficiency shortened SOD1 survival with accumulated abnormal astrocytes; manipulating selected lymphocyte populations did not substantially alter survival.", "what_it_does_not_show": "Innate signaling can protect the motor-neuron environment, and cell correlations do not by themselves prove which abnormal astrocyte state mediates the whole effect.", "confounders_present": [ "Innate signaling can protect the motor-neuron environment, and cell correlations do not by themselves prove which abnormal astrocyte state mediates the whole effect." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 52, "pmid": "24607225", "title": "Microglia induce motor neuron death via the classical NF-κB pathway in amyotrophic lateral sclerosis.", "citation": "Frakes AE, Ferraiuolo L, Haidet-Phillips AM et al. Microglia induce motor neuron death via the classical NF-κB pathway in amyotrophic lateral sclerosis. Neuron. 2014.", "doi": "10.1016/j.neuron.2014.01.013", "pmcid": "PMC3978641", "url": "https://pubmed.ncbi.nlm.nih.gov/24607225/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/24607225/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID24607225", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph8, 1:RESULTS:paragraph9, 1:RESULTS:paragraph12, 1:RESULTS:paragraph13. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Microglial NFκB suppression extended ALS-mouse survival, whereas astrocytic suppression did not rescue motor-neuron death; microglial activation caused death in culture and in vivo.", "what_it_does_not_show": "The endogenous pathway perturbation is cell-resolved, but forced constitutive activation and SOD1 genotype restrict broad human or inflammation-first inference. Original Results: CSF1R-Cre acts in the mononuclear phagocyte lineage, although spinal reporter staining is restricted to microglia. Homozygous IKKβ deletion caused serious immune dysfunction, so survival was assessed in heterozygotes. Median survival rose from 133 to 153 days, onset was unchanged, and mutant SOD1 abundance was unchanged. Forced NFκB activation also kills neurons, but is not physiological initiation.", "confounders_present": [ "The endogenous pathway perturbation is cell-resolved, but forced constitutive activation and SOD1 genotype restrict broad human or inflammation-first inference. Original Results: CSF1R-Cre acts in the mononuclear phagocyte lineage, although spinal reporter staining is restricted to microglia. Homozygous IKKβ deletion caused serious immune dysfunction, so survival was assessed in heterozygotes. Median survival rose from 133 to 153 days, onset was unchanged, and mutant SOD1 abundance was unchanged. Forced NFκB activation also kills neurons, but is not physiological initiation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "SOD1-G93A disease platform; CSF1R-Cre includes peripheral myeloid cells." ] }, { "n": 53, "pmid": "23254930", "title": "NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice.", "citation": "Heneka MT, Kummer MP, Stutz A et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 2013.", "doi": "10.1038/nature11729", "pmcid": "PMC3812809", "url": "https://pubmed.ncbi.nlm.nih.gov/23254930/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/23254930/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID23254930", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "NLRP3 or caspase1 loss preserved spatial memory and increased amyloid clearance in APP/PS1, with reduced inflammatory activity and amyloid burden.", "what_it_does_not_show": "Constitutive global immune loss and familial amyloid background are limited scopes; downstream response to amyloid can still mediate causal decline.", "confounders_present": [ "Constitutive global immune loss and familial amyloid background are limited scopes; downstream response to amyloid can still mediate causal decline." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 54, "pmid": "26921617", "title": "Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-β pathology.", "citation": "Spangenberg EE, Lee RJ, Najafi AR et al. Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-β pathology. Brain : a journal of neurology. 2016.", "doi": "10.1093/brain/aww016", "pmcid": "PMC5006229", "url": "https://pubmed.ncbi.nlm.nih.gov/26921617/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26921617/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID26921617", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "One-month CSF1R inhibition in ten-month 5xFAD removed most microglia and preserved neuronal/spine endpoints and contextual memory without reducing amyloid.", "what_it_does_not_show": "This is a post-pathology causal contribution; systemic receptor pharmacology and total-cell removal are broader than a single harmful state, and protective contexts elsewhere remain.", "confounders_present": [ "This is a post-pathology causal contribution; systemic receptor pharmacology and total-cell removal are broader than a single harmful state, and protective contexts elsewhere remain." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 55, "pmid": "23150934", "title": "TREM2 variants in Alzheimer's disease.", "citation": "Guerreiro R, Wojtas A, Bras J et al. TREM2 variants in Alzheimer's disease. The New England journal of medicine. 2013.", "doi": "10.1056/NEJMoa1211851", "pmcid": "PMC3631573", "url": "https://pubmed.ncbi.nlm.nih.gov/23150934/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/23150934/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID23150934", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Original discovery and replication genotyping plus GWAS meta-analysis linked rare TREM2 variants to AD risk.", "what_it_does_not_show": "This is a primary genetic cohort report despite its meta-analysis component; genetic immune dysfunction does not identify uniformly harmful chronic activation or a specific inflammatory mediator.", "confounders_present": [ "This is a primary genetic cohort report despite its meta-analysis component; genetic immune dysfunction does not identify uniformly harmful chronic activation or a specific inflammatory mediator." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Discovery/replication cohorts and meta-analysis may overlap later genetic syntheses." ] }, { "n": 56, "pmid": "23150908", "title": "Variant of TREM2 associated with the risk of Alzheimer's disease.", "citation": "Jonsson T, Stefansson H, Steinberg S et al. Variant of TREM2 associated with the risk of Alzheimer's disease. The New England journal of medicine. 2013.", "doi": "10.1056/NEJMoa1211103", "pmcid": "PMC3677583", "url": "https://pubmed.ncbi.nlm.nih.gov/23150908/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/23150908/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID23150908", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Icelandic sequencing/imputation and international replication associated TREM2-R47H with about threefold AD risk and poorer cognition in unaffected elderly carriers.", "what_it_does_not_show": "The variant's immune/clearance mechanism needs separate functional identification; protective microglial failure is as relevant as excess inflammation, and replication cohorts may overlap other reports.", "confounders_present": [ "The variant's immune/clearance mechanism needs separate functional identification; protective microglial failure is as relevant as excess inflammation, and replication cohorts may overlap other reports." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 57, "pmid": "28714976", "title": "Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease.", "citation": "Sims R, van der Lee SJ, Naj AC et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature genetics. 2017.", "doi": "10.1038/ng.3916", "pmcid": "PMC5669039", "url": "https://pubmed.ncbi.nlm.nih.gov/28714976/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28714976/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID28714976", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Three-stage genotyping in 85133 participants identified protective PLCG2-P522R and risk-increasing ABI3/TREM2 coding variants enriched in microglial pathways.", "what_it_does_not_show": "The genetic evidence supports immune-function involvement, while protection from enhanced PLCG2 function contradicts equating activation magnitude with harm; mechanistic mediation remains separate.", "confounders_present": [ "The genetic evidence supports immune-function involvement, while protection from enhanced PLCG2 function contradicts equating activation magnitude with harm; mechanistic mediation remains separate." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 58, "pmid": "17460158", "title": "Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.", "citation": "ADAPT Research Group, Lyketsos CG, Breitner JC et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007.", "doi": "10.1212/01.wnl.0000260269.93245.d2", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/17460158/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/17460158/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "ADAPT-original-randomization", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "Early ADAPT results found no prevention benefit from naproxen or celecoxib, with stopped treatment and unexpected prevalent cognitive disease at entry.", "what_it_does_not_show": "Early imprecision and enrollment/treatment interruption limit interpretation; systemic NSAIDs do not selectively remove a defined glial state.", "confounders_present": [ "Early imprecision and enrollment/treatment interruption limit interpretation; systemic NSAIDs do not selectively remove a defined glial state." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 59, "pmid": "23562431", "title": "Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT).", "citation": "Alzheimer's Disease Anti-inflammatory Prevention Trial Research Group. Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimer's & dementia : the journal of the Alzheimer's Association. 2013.", "doi": "10.1016/j.jalz.2012.11.012", "pmcid": "PMC3823756", "url": "https://pubmed.ncbi.nlm.nih.gov/23562431/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/23562431/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "ADAPT-original-randomization", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "ADAPT follow-up across approximately seven years found no overall AD incidence reduction after a median under 1.5 years of assigned NSAID treatment.", "what_it_does_not_show": "Same randomized cohort as early ADAPT, not independent replication; delayed follow-up does not equal continuous long-term exposure or specific glial engagement.", "confounders_present": [ "Same randomized cohort as early ADAPT, not independent replication; delayed follow-up does not equal continuous long-term exposure or specific glial engagement." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 60, "pmid": "12783912", "title": "Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.", "citation": "Aisen PS, Schafer KA, Grundman M et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003.", "doi": "10.1001/jama.289.21.2819", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/12783912/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/12783912/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID12783912", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "In 351 mild-to-moderate AD participants, one-year naproxen or rofecoxib did not slow the ADAS-Cog primary outcome or show consistent secondary benefit.", "what_it_does_not_show": "COX inhibition and systemic adverse effects do not prove selective CNS mediator blockade; results constrain these doses and symptomatic-stage strategies.", "confounders_present": [ "COX inhibition and systemic adverse effects do not prove selective CNS mediator blockade; results constrain these doses and symptomatic-stage strategies." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 61, "pmid": "33778150", "title": "Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer's disease.", "citation": "Potter H, Woodcock JH, Boyd TD et al. Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer's disease. Alzheimer's & dementia (New York, N. Y.). 2021.", "doi": "10.1002/trc2.12158", "pmcid": "PMC7988877", "url": "https://pubmed.ncbi.nlm.nih.gov/33778150/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33778150/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID33778150", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 2:RESULTS:paragraph11, 2:RESULTS:paragraph14, 2:RESULTS:paragraph16, 2:RESULTS:paragraph19, 2:RESULTS:paragraph23, 1:METHODS. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "A 40-person randomized AD study found short-term MMSE improvement after three weeks of sargramostim, with peripheral immune and plasma biomarker changes.", "what_it_does_not_show": "Safety-primary small study and brief cognitive effects do not establish sustained disease modification or a CNS glial mechanism; broader outcome and baseline details require original sections. Original Results and Methods: 40-person, three-week safety-primary trial. Baseline MMSE imbalance complicates the positive MMSE signal; baseline-adjusted end-of-treatment significance is lost, although the first follow-up remains positive. ADAS-Cog13 worsens at that follow-up, ADL/CDR-SB are null and the small PET subset is null. This is a mixed exploratory efficacy pattern, not established sustained benefit.", "confounders_present": [ "Safety-primary small study and brief cognitive effects do not establish sustained disease modification or a CNS glial mechanism; broader outcome and baseline details require original sections. Original Results and Methods: 40-person, three-week safety-primary trial. Baseline MMSE imbalance complicates the positive MMSE signal; baseline-adjusted end-of-treatment significance is lost, although the first follow-up remains positive. ADAS-Cog13 worsens at that follow-up, ADL/CDR-SB are null and the small PET subset is null. This is a mixed exploratory efficacy pattern, not established sustained benefit." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 62, "pmid": "31745214", "title": "Necroptosis is dispensable for motor neuron degeneration in a mouse model of ALS.", "citation": "Wang T, Perera ND, Chiam MDF et al. Necroptosis is dispensable for motor neuron degeneration in a mouse model of ALS. Cell death and differentiation. 2020.", "doi": "10.1038/s41418-019-0457-8", "pmcid": "PMC7206015", "url": "https://pubmed.ncbi.nlm.nih.gov/31745214/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31745214/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID31745214", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "null", "what_it_shows": "MLKL ablation did not change SOD1 onset, progression, survival, neuron degeneration or glial activation despite prior necroptosis-pathway claims.", "what_it_does_not_show": "This is a terminal-effector null in one familial model, not exclusion of every inflammatory pathway; expression-marker accumulation is insufficient mechanism evidence.", "confounders_present": [ "This is a terminal-effector null in one familial model, not exclusion of every inflammatory pathway; expression-marker accumulation is insufficient mechanism evidence." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 63, "pmid": "18931666", "title": "Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease.", "citation": "Lepore AC, Rauck B, Dejea C et al. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nature neuroscience. 2008.", "doi": "10.1038/nn.2210", "pmcid": "PMC2656686", "url": "https://pubmed.ncbi.nlm.nih.gov/18931666/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/18931666/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID18931666", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "Normal astrocyte-precursor transplantation in SOD1 rats reduced microgliosis, preserved motor neurons and respiratory/motor function and extended survival, partly through GLT1.", "what_it_does_not_show": "Transplantation restores trophic/glutamate functions as well as inflammation; focal familial-model benefit does not isolate one harmful reactive state.", "confounders_present": [ "Transplantation restores trophic/glutamate functions as well as inflammation; focal familial-model benefit does not isolate one harmful reactive state." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 64, "pmid": "22523565", "title": "Ablation of proliferating cells in the CNS exacerbates motor neuron disease caused by mutant superoxide dismutase.", "citation": "Audet JN, Gowing G, Paradis R et al. Ablation of proliferating cells in the CNS exacerbates motor neuron disease caused by mutant superoxide dismutase. PloS one. 2012.", "doi": "10.1371/journal.pone.0034932", "pmcid": "PMC3327706", "url": "https://pubmed.ncbi.nlm.nih.gov/22523565/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/22523565/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID22523565", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "AraC removal of proliferating CNS cells accelerated SOD1 progression while reducing microglia, progenitors and T cells.", "what_it_does_not_show": "Multiple cell classes and anti-mitotic effects prevent attributing harm specifically to microglial loss, but contradict indiscriminate suppression as a universal strategy.", "confounders_present": [ "Multiple cell classes and anti-mitotic effects prevent attributing harm specifically to microglial loss, but contradict indiscriminate suppression as a universal strategy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 65, "pmid": "30815534", "title": "Deletion of Ripk3 Prevents Motor Neuron Death In Vitro but not In Vivo.", "citation": "Dermentzaki G, Politi KA, Lu L et al. Deletion of Ripk3 Prevents Motor Neuron Death In Vitro but not In Vivo. eNeuro. 2019.", "doi": "10.1523/ENEURO.0308-18.2018", "pmcid": "PMC6391588", "url": "https://pubmed.ncbi.nlm.nih.gov/30815534/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30815534/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID30815534", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "null", "what_it_shows": "RIPK3 silencing protected cultured neurons from SOD1 astrocytes, but genetic deletion did not improve mouse behavior or neuropathology.", "what_it_does_not_show": "Culture rescue failed organismal follow-through for this mediator; it cannot be generalized as proof that all glial toxicity pathways are merely reactive.", "confounders_present": [ "Culture rescue failed organismal follow-through for this mediator; it cannot be generalized as proof that all glial toxicity pathways are merely reactive." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 66, "pmid": "18086918", "title": "MyD88-deficient bone marrow cells accelerate onset and reduce survival in a mouse model of amyotrophic lateral sclerosis.", "citation": "Kang J, Rivest S et al. MyD88-deficient bone marrow cells accelerate onset and reduce survival in a mouse model of amyotrophic lateral sclerosis. The Journal of cell biology. 2007.", "doi": "10.1083/jcb.200705046", "pmcid": "PMC2140021", "url": "https://pubmed.ncbi.nlm.nih.gov/18086918/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/18086918/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID18086918", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "MyD88-deficient marrow transplantation advanced onset and shortened survival in SOD1-G37R mice relative to competent donor cells.", "what_it_does_not_show": "Marrow conditioning and peripheral/engrafted myeloid contributions differ from native resident microglial activation; immune signaling was protective in this tested context.", "confounders_present": [ "Marrow conditioning and peripheral/engrafted myeloid contributions differ from native resident microglial activation; immune signaling was protective in this tested context." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 67, "pmid": "32719333", "title": "Knockout of reactive astrocyte activating factors slows disease progression in an ALS mouse model.", "citation": "Guttenplan KA, Weigel MK, Adler DI et al. Knockout of reactive astrocyte activating factors slows disease progression in an ALS mouse model. Nature communications. 2020.", "doi": "10.1038/s41467-020-17514-9", "pmcid": "PMC7385161", "url": "https://pubmed.ncbi.nlm.nih.gov/32719333/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32719333/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID32719333", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph2, 1:Results:paragraph3, 1:Results:paragraph4, 1:Results:paragraph5, 1:Results:paragraph7. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Combined IL1a, TNF and C1q knockout extended SOD1-G93A survival and interrogated the proposed microglia-to-reactive-astrocyte pathway.", "what_it_does_not_show": "Global lifelong cytokine deletion is not astrocyte-specific loss; rescue, stage timing and alternative immune effects require body checks before attributing all benefit to one state. Original Results: lifelong global IL1α/TNF/C1q triple deletion delays motor-neuron loss and denervation rather than preventing eventual disease; mutant animals reach a later endpoint with similar loss. Disease onset remains similar. This is causal progression modification with a constitutive, systemic intervention.", "confounders_present": [ "Global lifelong cytokine deletion is not astrocyte-specific loss; rescue, stage timing and alternative immune effects require body checks before attributing all benefit to one state. Original Results: lifelong global IL1α/TNF/C1q triple deletion delays motor-neuron loss and denervation rather than preventing eventual disease; mutant animals reach a later endpoint with similar loss. Disease onset remains similar. This is causal progression modification with a constitutive, systemic intervention." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "SOD1 mouse lineage also underlies several separate glial perturbation reports." ] }, { "n": 68, "pmid": "36890231", "title": "Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy.", "citation": "Chen X, Firulyova M, Manis M et al. Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy. Nature. 2023.", "doi": "10.1038/s41586-023-05788-0", "pmcid": "PMC10258627", "url": "https://pubmed.ncbi.nlm.nih.gov/36890231/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36890231/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "ErratumIn: PMID39415023" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID36890231", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 2:Interaction of microglia and T cells:paragraph2, 2:Interaction of microglia and T cells:paragraph3, 3:T cell depletion prevent degeneration:paragraph0, 3:T cell depletion prevent degeneration:paragraph1. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Microglial or T-cell depletion blocked tau-model degeneration, while IFNγ or PDCD1 inhibition ameliorated atrophy; human AD tissue contained expanded cytotoxic T cells.", "what_it_does_not_show": "Adaptive and innate immune effects form a causal model hub downstream of tau, rather than proving all human activation is an initiating driver; linked correction remains attached. Original Results: peripheral T-cell depletion from 6 to 9.5 months reduces atrophy, NfL and functional deficits versus IgG controls; IFNγ blockade begins at 7.5 months and PLX3397 at 8.5 months. PLX3397 targets CSF1R, c-kit and FLT3. Tau burden also changes, and neither intervention isolates a glial-only mediator. Original results verify better Y-maze/auditory-cue performance and baseline locomotor controls; contextual freezing was only a trend.", "confounders_present": [ "Adaptive and innate immune effects form a causal model hub downstream of tau, rather than proving all human activation is an initiating driver; linked correction remains attached. Original Results: peripheral T-cell depletion from 6 to 9.5 months reduces atrophy, NfL and functional deficits versus IgG controls; IFNγ blockade begins at 7.5 months and PLX3397 at 8.5 months. PLX3397 targets CSF1R, c-kit and FLT3. Tau burden also changes, and neither intervention isolates a glial-only mediator. Original results verify better Y-maze/auditory-cue performance and baseline locomotor controls; contextual freezing was only a trend." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "P301S/APOE lineage and laboratory overlap with astrocytic APOE and TREM2 tau studies." ] }, { "n": 69, "pmid": "29073081", "title": "TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy.", "citation": "Leyns CEG, Ulrich JD, Finn MB et al. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proceedings of the National Academy of Sciences of the United States of America. 2017.", "doi": "10.1073/pnas.1710311114", "pmcid": "PMC5663386", "url": "https://pubmed.ncbi.nlm.nih.gov/29073081/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29073081/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID29073081", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Trem2 deletion reduced microgliosis and preserved brain volume in PS19 despite similar phosphorylated/insoluble tau.", "what_it_does_not_show": "This separates tau burden from immune-associated atrophy in a pure-tau background; amyloid and APOE4 experiments reverse or alter the direction, restricting generalization.", "confounders_present": [ "This separates tau burden from immune-associated atrophy in a pure-tau background; amyloid and APOE4 experiments reverse or alter the direction, restricting generalization." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] } ], "verification_summary": { "load_bearing_claims_checked": 74, "verified": 74, "unverified": 0, "contradicted": 0, "note": "Verified attribution is distinct from mechanism truth or complete body access." }, "factual_issues_found": [], "cap_rules_applied": [], "cap_precedence_resolutions": [ { "collision": "Perturbation in a defined setting versus broader inference", "subclaim_scope_cap_binds_on": "Chronic microglial and astrocytic activation is a causal driver of neurodegeneration rather than a reactive response to it.", "subclaim_scope_threshold_binds_on": "The precise experimentally tested subclaim scope", "resolution": "The primary neurodegeneration and secondary immunology rubrics agree that endogenous mediator perturbation supports causal contribution in the tested context. Mutant SOD1 or tau overexpression alone is not strong causal evidence; mediator deletion, timing and survival/function contrasts provide an additional causal test. That distinction permits Ε for bounded SC2/SC3 while leaving broad SC4 at Γ. Protective immune-state interventions count as contradictions to a pan-activation claim, not as grounds to deny all inflammatory causality. Independent convergence is assessed as a set, without imposing an impossible universal RCT.", "note": "Convergent lines are assessed as a set; one weak leg is not re-capped over the assembled case." } ], "boundary_check_BGD": [ { "subclaim_id": "SC1", "field_valid_perturbation_quote": "\n- Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo\n- Selective pathway inhibition that changes onset/progression while preserving broader viability\n- Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "PMID17203472, PMID27033548, PMID35394877, PMID28099414, PMID28602351", "gamma_hard_rules_triggered": [ "Pure histology and biomarker association alone cannot establish direction.", "Endogenous mediator deletion in a mutant disease background supports the tested context, not automatic sporadic-human generalization.", "Reactive causal amplification is distinguished from both passive response and an obligatory initiator.", "The assembled set is assessed for complementary failure modes; trial count or source count is not convergence." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Presymptomatic animal changes and human preclinical/longitudinal observations exceed terminal colocalization alone. Human state ordering and direct neuronal-loss mediation remain unresolved; pseudotime and structural equation modeling do not identify an initiating event.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC2", "field_valid_perturbation_quote": "\n- Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo\n- Selective pathway inhibition that changes onset/progression while preserving broader viability\n- Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "PMID34262178, PMID37029500, PMID39167665, PMID29892066, PMID30381407, PMID37118504, PMID17203472, PMID33046546, PMID29624735, PMID27033548, PMID28802038, PMID36306735, PMID37442133, PMID36989373, PMID25728668, PMID31257024, PMID32544086, PMID35794654, PMID34716339, PMID35394877, PMID33831349, PMID30734229, PMID28099414, PMID28602351, PMID39059388, PMID31748742, PMID34825707, PMID29293211, PMID32579671, PMID36368315, PMID32917267, PMID30635357, PMID25384799, PMID18246065, PMID16741123, PMID25892237, PMID29568058, PMID24607225, PMID23254930, PMID26921617, PMID18931666, PMID22523565, PMID18086918, PMID32719333, PMID36890231, PMID29073081", "gamma_hard_rules_triggered": [ "Pure histology and biomarker association alone cannot establish direction.", "Endogenous mediator deletion in a mutant disease background supports the tested context, not automatic sporadic-human generalization.", "Reactive causal amplification is distinguished from both passive response and an obligatory initiator.", "The assembled set is assessed for complementary failure modes; trial count or source count is not convergence." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Endogenous cell-lineage perturbations of mutant SOD1, NFκB and astrocytic APOE, as well as complementary immune manipulations, materially alter survival, atrophy or function in specified models. Defined mediator causality crosses Δ and merits Ε with explicit genotype, state and timing restrictions. Protective SYK, TREM2, IL3 and innate signaling states rule out indiscriminate activation suppression.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC3", "field_valid_perturbation_quote": "\n- Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo\n- Selective pathway inhibition that changes onset/progression while preserving broader viability\n- Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "PMID34262178, PMID37029500, PMID39167665, PMID29892066, PMID30381407, PMID37118504, PMID17203472, PMID33046546, PMID29624735, PMID27033548, PMID28802038, PMID36306735, PMID37442133, PMID36989373, PMID25728668, PMID31257024, PMID32544086, PMID35794654, PMID34716339, PMID35394877, PMID33831349, PMID30734229, PMID28099414, PMID39059388, PMID31748742, PMID34825707, PMID29293211, PMID36368315, PMID30635357, PMID25384799, PMID18246065, PMID16741123, PMID25892237, PMID29568058, PMID24607225, PMID23254930, PMID26921617, PMID18931666, PMID22523565, PMID18086918, PMID32719333, PMID36890231, PMID29073081", "gamma_hard_rules_triggered": [ "Pure histology and biomarker association alone cannot establish direction.", "Endogenous mediator deletion in a mutant disease background supports the tested context, not automatic sporadic-human generalization.", "Reactive causal amplification is distinguished from both passive response and an obligatory initiator.", "The assembled set is assessed for complementary failure modes; trial count or source count is not convergence." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Glial contributions exceed a passive bystander or clearance-only account. SOD1 removal in glia and partial NFκB suppression slow later progression without changing onset; these are reactive causal amplification, which qualifies under the registered wording. Astrocyte and microglial effects are not interchangeable and do not establish obligatory upstream initiation. This defined causal contribution is Ε.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC4", "field_valid_perturbation_quote": "\n- Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo\n- Selective pathway inhibition that changes onset/progression while preserving broader viability\n- Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "PMID40792655, PMID32579671, PMID39444037, PMID32917267, PMID28649610, PMID33778150", "gamma_hard_rules_triggered": [ "Pure histology and biomarker association alone cannot establish direction.", "Endogenous mediator deletion in a mutant disease background supports the tested context, not automatic sporadic-human generalization.", "Reactive causal amplification is distinguished from both passive response and an obligatory initiator.", "The assembled set is assessed for complementary failure modes; trial count or source count is not convergence." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "AD, PD and ALS models show context-dependent causal immune effects, but human pathway engagement has not reliably produced sustained clinical benefit. AL002, NLY01, AZA-PD, ADAPT, NSAID treatment and minocycline test different, incompletely selective mechanisms. Protective and harmful states require prospective boundaries; the general disease-class claim remains Γ.", "ceiling_from_boundary_check": "Γ" } ], "thresholds_tested": [ { "subclaim_id": "SC1", "threshold": "Δ", "requirement_quoted": "Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.", "satisfied": "no", "supporting_evidence": [ "[9] A single high-dose systemic LPS or TNF exposure caused sustained brain inflammation and delayed progressive TH-positive nigral-neuron loss, with TNF-receptor comparisons.", "[12] C1q, C3 and CR3 inhibition reduced early amyloid-associated synapse loss; C1q was required for oligomer-induced synaptic and LTP toxicity in the tested models.", "[24] STING activation preceded dopamine-neuron loss after synuclein fibrils; STING-deficient mice resisted motor, aggregate and neuronal-loss phenotypes.", "[28] Microglial IL1a, TNF and C1q induced toxic reactive astrocytes; blocking formation protected axotomized neurons, and human disease tissue contained the state.", "[29] Single-cell mapping and Trem2 loss separated two disease-associated microglial activation phases, with intracellular amyloid in mapped cells." ], "what_would_cross_it": "Prospective, state-resolved human measurements must precede independently measured injury without relying solely on terminal tissue or inferred pseudotime." }, { "subclaim_id": "SC2", "threshold": "Δ", "requirement_quoted": "Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.", "satisfied": "yes", "supporting_evidence": [ "[2] Astrocytic IL-3 programs microglial motility and aggregate clearance and restricts pathology and cognitive decline in tested AD models.", "[4] Parkin loss increased LPS-triggered microglial NLRP3 assembly, motor impairment and dopaminergic loss; Parkin overexpression and HSP90 inhibition interrogated NLRP3 degradation.", "[5] Microglia-specific IL-10 delivery protected dopaminergic neurons in SNCA-overexpressing mice while inducing an activated prophagocytic microglial state and lymphocyte regulation.", "[6] NLY01 reduced dopaminergic loss and behavioral deficits after synuclein fibrils and prolonged survival in A53T mice, associated with reduced neurotoxic astrocyte conversion.", "[7] MCC950 inhibited NLRP3 activity and improved motor, dopamine-neuron and aggregate endpoints in several rodent PD models; degeneration itself could activate the pathway.", "[8] C1q deletion reduced microglial and astrocytic synapse engulfment and restored density in TauP301S; astrocytic engulfment compensated when Trem2-dependent microglial phagocytosis failed.", "[9] A single high-dose systemic LPS or TNF exposure caused sustained brain inflammation and delayed progressive TH-positive nigral-neuron loss, with TNF-receptor comparisons.", "[10] Human iPSC astrocytes reduced neuronal synuclein accumulation and transfer through lysosomal clearance; ATP13A2-deficient astrocytes lost part of this protection.", "[11] Cx3cr1 deficiency worsened AAV-A53T synuclein inflammation and dopaminergic degeneration, while wild-type synuclein injury was similar across receptor genotypes.", "[12] C1q, C3 and CR3 inhibition reduced early amyloid-associated synapse loss; C1q was required for oligomer-induced synaptic and LTP toxicity in the tested models.", "[13] TREM2 deficiency impaired microglial metabolism, and cyclocreatine restored plaque clustering while reducing adjacent neuronal dystrophy.", "[14] Microglial SYK deficiency impaired plaque encasement and worsened pathology and behavior; CLEC7A activation rescued microglial activation in TREM2-R47H mice.", "[15] TREM2-C1q binding restrained complement activation; haploinsufficiency worsened synapse engulfment and a binding peptide rescued synaptic impairment in tested models.", "[16] Nptx2 loss increased C1q-dependent microglial synapse removal, while neuronal Nptx2 overexpression restrained complement and synapse loss in aged tau mice.", "[17] TREM2 loss impaired damage-lipid sensing, microglial plaque clustering and survival and increased amyloid accumulation in 5xFAD.", "[18] Myeloid or microglial LANDO loss increased cytokines and neurotoxic amyloid, with accelerated degeneration, altered signaling and memory deficits.", "[19] Human TREM2-R47H in PS19 reduced microglial reactivity, synapse phagocytosis, atrophy and synapse loss versus the common variant.", "[22] C7 antibody and C6 knockout reduced plaque-adjacent spine/synapse loss in two AD models, implicating terminal complement activity.", "[23] Microglia-selective synuclein overexpression caused dopamine-neuron degeneration without neuronal synuclein aggregation, and oxidative/nitrosative inhibition attenuated damage.", "[24] STING activation preceded dopamine-neuron loss after synuclein fibrils; STING-deficient mice resisted motor, aggregate and neuronal-loss phenotypes.", "[25] Inducible astrocytic APOE4 removal after tau pathology onset reduced neurodegeneration, synapse loss and microglial synaptic phagocytosis.", "[27] Intracerebral clodronate depleted microglia but also damaged vascular integrity, reduced neural markers and increased inflammatory/glial signals; neuronal ATP fell in culture.", "[28] Microglial IL1a, TNF and C1q induced toxic reactive astrocytes; blocking formation protected axotomized neurons, and human disease tissue contained the state.", "[29] Single-cell mapping and Trem2 loss separated two disease-associated microglial activation phases, with intracellular amyloid in mapped cells.", "[30] Microglial nanotube contacts removed neuronal tau/synuclein aggregates, supplied healthy mitochondria and restored activity; mitochondrial poisoning removed protection.", "[31] NLRP3 loss reduced tau phosphorylation/aggregation, and amyloid-homogenate-induced tau pathology depended on NLRP3; tau itself activated the inflammasome.", "[33] Microglial PD1 deletion increased inflammation and impaired amyloid uptake, with more plaque deposition in APP/PS1.", "[34] ASC specks promoted amyloid cross-seeding after hippocampal delivery, and ASC deficiency or antibody coapplication blocked induced pathology.", "[35] AL002c stimulated microglial proliferation and reduced filamentous plaques and neurite dystrophy in a human-TREM2 AD model; first-human fluid engagement was also reported.", "[36] TREM2 knockout worsened tau pathology and degeneration in P301S/APOE4 despite reduced TREM2-dependent microgliosis.", "[38] The AD-protective PLCG2-P522R knock-in increased enzyme activity, macrophage survival/acute responses and measures of microglial function.", "[45] Heterozygous TBK1 loss advanced SOD1 onset/denervation but reduced late microglial inflammation, slowed progression and extended survival.", "[46] xCT deletion reduced microglial glutamate and inflammatory outputs and slowed late SOD1 degeneration with more surviving motor neurons, despite earlier symptom onset.", "[48] Conditional mutant-SOD1 reduction in astrocytes left onset unchanged but delayed microglial activation and sharply slowed later progression.", "[49] Cell-resolved mutant-SOD1 deletion separated motor-neuron-determined onset/early progression from microglial effects on late progression.", "[50] Astrocytic TGFβ1 overproduction worsened SOD1 progression while deactivating protective microglia/T cells; post-onset signaling inhibition extended survival.", "[51] TRIF deficiency shortened SOD1 survival with accumulated abnormal astrocytes; manipulating selected lymphocyte populations did not substantially alter survival.", "[52] Microglial NFκB suppression extended ALS-mouse survival, whereas astrocytic suppression did not rescue motor-neuron death; microglial activation caused death in culture and in vivo.", "[53] NLRP3 or caspase1 loss preserved spatial memory and increased amyloid clearance in APP/PS1, with reduced inflammatory activity and amyloid burden.", "[54] One-month CSF1R inhibition in ten-month 5xFAD removed most microglia and preserved neuronal/spine endpoints and contextual memory without reducing amyloid.", "[63] Normal astrocyte-precursor transplantation in SOD1 rats reduced microgliosis, preserved motor neurons and respiratory/motor function and extended survival, partly through GLT1.", "[64] AraC removal of proliferating CNS cells accelerated SOD1 progression while reducing microglia, progenitors and T cells.", "[66] MyD88-deficient marrow transplantation advanced onset and shortened survival in SOD1-G37R mice relative to competent donor cells.", "[67] Combined IL1a, TNF and C1q knockout extended SOD1-G93A survival and interrogated the proposed microglia-to-reactive-astrocyte pathway.", "[68] Microglial or T-cell depletion blocked tau-model degeneration, while IFNγ or PDCD1 inhibition ameliorated atrophy; human AD tissue contained expanded cytotoxic T cells.", "[69] Trem2 deletion reduced microgliosis and preserved brain volume in PS19 despite similar phosphorylated/insoluble tau." ], "what_would_cross_it": "" }, { "subclaim_id": "SC2", "threshold": "Ε", "requirement_quoted": "Requires causal support in a defined context, but with clear restriction by subtype, disease stage, model, or tissue.\n\nUse Ε when there is a real causal contribution, but generalization to the entire disease class fails.", "satisfied": "yes", "supporting_evidence": [ "[2] Astrocytic IL-3 programs microglial motility and aggregate clearance and restricts pathology and cognitive decline in tested AD models.", "[4] Parkin loss increased LPS-triggered microglial NLRP3 assembly, motor impairment and dopaminergic loss; Parkin overexpression and HSP90 inhibition interrogated NLRP3 degradation.", "[5] Microglia-specific IL-10 delivery protected dopaminergic neurons in SNCA-overexpressing mice while inducing an activated prophagocytic microglial state and lymphocyte regulation.", "[6] NLY01 reduced dopaminergic loss and behavioral deficits after synuclein fibrils and prolonged survival in A53T mice, associated with reduced neurotoxic astrocyte conversion.", "[7] MCC950 inhibited NLRP3 activity and improved motor, dopamine-neuron and aggregate endpoints in several rodent PD models; degeneration itself could activate the pathway.", "[8] C1q deletion reduced microglial and astrocytic synapse engulfment and restored density in TauP301S; astrocytic engulfment compensated when Trem2-dependent microglial phagocytosis failed.", "[9] A single high-dose systemic LPS or TNF exposure caused sustained brain inflammation and delayed progressive TH-positive nigral-neuron loss, with TNF-receptor comparisons.", "[10] Human iPSC astrocytes reduced neuronal synuclein accumulation and transfer through lysosomal clearance; ATP13A2-deficient astrocytes lost part of this protection.", "[11] Cx3cr1 deficiency worsened AAV-A53T synuclein inflammation and dopaminergic degeneration, while wild-type synuclein injury was similar across receptor genotypes.", "[12] C1q, C3 and CR3 inhibition reduced early amyloid-associated synapse loss; C1q was required for oligomer-induced synaptic and LTP toxicity in the tested models.", "[13] TREM2 deficiency impaired microglial metabolism, and cyclocreatine restored plaque clustering while reducing adjacent neuronal dystrophy.", "[14] Microglial SYK deficiency impaired plaque encasement and worsened pathology and behavior; CLEC7A activation rescued microglial activation in TREM2-R47H mice.", "[15] TREM2-C1q binding restrained complement activation; haploinsufficiency worsened synapse engulfment and a binding peptide rescued synaptic impairment in tested models.", "[16] Nptx2 loss increased C1q-dependent microglial synapse removal, while neuronal Nptx2 overexpression restrained complement and synapse loss in aged tau mice.", "[17] TREM2 loss impaired damage-lipid sensing, microglial plaque clustering and survival and increased amyloid accumulation in 5xFAD.", "[18] Myeloid or microglial LANDO loss increased cytokines and neurotoxic amyloid, with accelerated degeneration, altered signaling and memory deficits.", "[19] Human TREM2-R47H in PS19 reduced microglial reactivity, synapse phagocytosis, atrophy and synapse loss versus the common variant.", "[22] C7 antibody and C6 knockout reduced plaque-adjacent spine/synapse loss in two AD models, implicating terminal complement activity.", "[23] Microglia-selective synuclein overexpression caused dopamine-neuron degeneration without neuronal synuclein aggregation, and oxidative/nitrosative inhibition attenuated damage.", "[24] STING activation preceded dopamine-neuron loss after synuclein fibrils; STING-deficient mice resisted motor, aggregate and neuronal-loss phenotypes.", "[25] Inducible astrocytic APOE4 removal after tau pathology onset reduced neurodegeneration, synapse loss and microglial synaptic phagocytosis.", "[27] Intracerebral clodronate depleted microglia but also damaged vascular integrity, reduced neural markers and increased inflammatory/glial signals; neuronal ATP fell in culture.", "[28] Microglial IL1a, TNF and C1q induced toxic reactive astrocytes; blocking formation protected axotomized neurons, and human disease tissue contained the state.", "[29] Single-cell mapping and Trem2 loss separated two disease-associated microglial activation phases, with intracellular amyloid in mapped cells.", "[30] Microglial nanotube contacts removed neuronal tau/synuclein aggregates, supplied healthy mitochondria and restored activity; mitochondrial poisoning removed protection.", "[31] NLRP3 loss reduced tau phosphorylation/aggregation, and amyloid-homogenate-induced tau pathology depended on NLRP3; tau itself activated the inflammasome.", "[33] Microglial PD1 deletion increased inflammation and impaired amyloid uptake, with more plaque deposition in APP/PS1.", "[34] ASC specks promoted amyloid cross-seeding after hippocampal delivery, and ASC deficiency or antibody coapplication blocked induced pathology.", "[35] AL002c stimulated microglial proliferation and reduced filamentous plaques and neurite dystrophy in a human-TREM2 AD model; first-human fluid engagement was also reported.", "[36] TREM2 knockout worsened tau pathology and degeneration in P301S/APOE4 despite reduced TREM2-dependent microgliosis.", "[38] The AD-protective PLCG2-P522R knock-in increased enzyme activity, macrophage survival/acute responses and measures of microglial function.", "[45] Heterozygous TBK1 loss advanced SOD1 onset/denervation but reduced late microglial inflammation, slowed progression and extended survival.", "[46] xCT deletion reduced microglial glutamate and inflammatory outputs and slowed late SOD1 degeneration with more surviving motor neurons, despite earlier symptom onset.", "[48] Conditional mutant-SOD1 reduction in astrocytes left onset unchanged but delayed microglial activation and sharply slowed later progression.", "[49] Cell-resolved mutant-SOD1 deletion separated motor-neuron-determined onset/early progression from microglial effects on late progression.", "[50] Astrocytic TGFβ1 overproduction worsened SOD1 progression while deactivating protective microglia/T cells; post-onset signaling inhibition extended survival.", "[51] TRIF deficiency shortened SOD1 survival with accumulated abnormal astrocytes; manipulating selected lymphocyte populations did not substantially alter survival.", "[52] Microglial NFκB suppression extended ALS-mouse survival, whereas astrocytic suppression did not rescue motor-neuron death; microglial activation caused death in culture and in vivo.", "[53] NLRP3 or caspase1 loss preserved spatial memory and increased amyloid clearance in APP/PS1, with reduced inflammatory activity and amyloid burden.", "[54] One-month CSF1R inhibition in ten-month 5xFAD removed most microglia and preserved neuronal/spine endpoints and contextual memory without reducing amyloid.", "[63] Normal astrocyte-precursor transplantation in SOD1 rats reduced microgliosis, preserved motor neurons and respiratory/motor function and extended survival, partly through GLT1.", "[64] AraC removal of proliferating CNS cells accelerated SOD1 progression while reducing microglia, progenitors and T cells.", "[66] MyD88-deficient marrow transplantation advanced onset and shortened survival in SOD1-G37R mice relative to competent donor cells.", "[67] Combined IL1a, TNF and C1q knockout extended SOD1-G93A survival and interrogated the proposed microglia-to-reactive-astrocyte pathway.", "[68] Microglial or T-cell depletion blocked tau-model degeneration, while IFNγ or PDCD1 inhibition ameliorated atrophy; human AD tissue contained expanded cytotoxic T cells.", "[69] Trem2 deletion reduced microgliosis and preserved brain volume in PS19 despite similar phosphorylated/insoluble tau." ], "what_would_cross_it": "" }, { "subclaim_id": "SC2", "threshold": "Ζ", "requirement_quoted": "Requires:\n- Multiple independent causal lines in vivo\n- Replication across at least two relevant systems\n- Narrowing of major alternative models", "satisfied": "no", "supporting_evidence": [ "[2] Astrocytic IL-3 programs microglial motility and aggregate clearance and restricts pathology and cognitive decline in tested AD models.", "[4] Parkin loss increased LPS-triggered microglial NLRP3 assembly, motor impairment and dopaminergic loss; Parkin overexpression and HSP90 inhibition interrogated NLRP3 degradation.", "[5] Microglia-specific IL-10 delivery protected dopaminergic neurons in SNCA-overexpressing mice while inducing an activated prophagocytic microglial state and lymphocyte regulation.", "[6] NLY01 reduced dopaminergic loss and behavioral deficits after synuclein fibrils and prolonged survival in A53T mice, associated with reduced neurotoxic astrocyte conversion.", "[7] MCC950 inhibited NLRP3 activity and improved motor, dopamine-neuron and aggregate endpoints in several rodent PD models; degeneration itself could activate the pathway.", "[8] C1q deletion reduced microglial and astrocytic synapse engulfment and restored density in TauP301S; astrocytic engulfment compensated when Trem2-dependent microglial phagocytosis failed.", "[9] A single high-dose systemic LPS or TNF exposure caused sustained brain inflammation and delayed progressive TH-positive nigral-neuron loss, with TNF-receptor comparisons.", "[10] Human iPSC astrocytes reduced neuronal synuclein accumulation and transfer through lysosomal clearance; ATP13A2-deficient astrocytes lost part of this protection.", "[11] Cx3cr1 deficiency worsened AAV-A53T synuclein inflammation and dopaminergic degeneration, while wild-type synuclein injury was similar across receptor genotypes.", "[12] C1q, C3 and CR3 inhibition reduced early amyloid-associated synapse loss; C1q was required for oligomer-induced synaptic and LTP toxicity in the tested models.", "[13] TREM2 deficiency impaired microglial metabolism, and cyclocreatine restored plaque clustering while reducing adjacent neuronal dystrophy.", "[14] Microglial SYK deficiency impaired plaque encasement and worsened pathology and behavior; CLEC7A activation rescued microglial activation in TREM2-R47H mice.", "[15] TREM2-C1q binding restrained complement activation; haploinsufficiency worsened synapse engulfment and a binding peptide rescued synaptic impairment in tested models.", "[16] Nptx2 loss increased C1q-dependent microglial synapse removal, while neuronal Nptx2 overexpression restrained complement and synapse loss in aged tau mice.", "[17] TREM2 loss impaired damage-lipid sensing, microglial plaque clustering and survival and increased amyloid accumulation in 5xFAD.", "[18] Myeloid or microglial LANDO loss increased cytokines and neurotoxic amyloid, with accelerated degeneration, altered signaling and memory deficits.", "[19] Human TREM2-R47H in PS19 reduced microglial reactivity, synapse phagocytosis, atrophy and synapse loss versus the common variant.", "[22] C7 antibody and C6 knockout reduced plaque-adjacent spine/synapse loss in two AD models, implicating terminal complement activity.", "[23] Microglia-selective synuclein overexpression caused dopamine-neuron degeneration without neuronal synuclein aggregation, and oxidative/nitrosative inhibition attenuated damage.", "[24] STING activation preceded dopamine-neuron loss after synuclein fibrils; STING-deficient mice resisted motor, aggregate and neuronal-loss phenotypes.", "[25] Inducible astrocytic APOE4 removal after tau pathology onset reduced neurodegeneration, synapse loss and microglial synaptic phagocytosis.", "[27] Intracerebral clodronate depleted microglia but also damaged vascular integrity, reduced neural markers and increased inflammatory/glial signals; neuronal ATP fell in culture.", "[28] Microglial IL1a, TNF and C1q induced toxic reactive astrocytes; blocking formation protected axotomized neurons, and human disease tissue contained the state.", "[29] Single-cell mapping and Trem2 loss separated two disease-associated microglial activation phases, with intracellular amyloid in mapped cells.", "[30] Microglial nanotube contacts removed neuronal tau/synuclein aggregates, supplied healthy mitochondria and restored activity; mitochondrial poisoning removed protection.", "[31] NLRP3 loss reduced tau phosphorylation/aggregation, and amyloid-homogenate-induced tau pathology depended on NLRP3; tau itself activated the inflammasome.", "[33] Microglial PD1 deletion increased inflammation and impaired amyloid uptake, with more plaque deposition in APP/PS1.", "[34] ASC specks promoted amyloid cross-seeding after hippocampal delivery, and ASC deficiency or antibody coapplication blocked induced pathology.", "[35] AL002c stimulated microglial proliferation and reduced filamentous plaques and neurite dystrophy in a human-TREM2 AD model; first-human fluid engagement was also reported.", "[36] TREM2 knockout worsened tau pathology and degeneration in P301S/APOE4 despite reduced TREM2-dependent microgliosis.", "[38] The AD-protective PLCG2-P522R knock-in increased enzyme activity, macrophage survival/acute responses and measures of microglial function.", "[45] Heterozygous TBK1 loss advanced SOD1 onset/denervation but reduced late microglial inflammation, slowed progression and extended survival.", "[46] xCT deletion reduced microglial glutamate and inflammatory outputs and slowed late SOD1 degeneration with more surviving motor neurons, despite earlier symptom onset.", "[48] Conditional mutant-SOD1 reduction in astrocytes left onset unchanged but delayed microglial activation and sharply slowed later progression.", "[49] Cell-resolved mutant-SOD1 deletion separated motor-neuron-determined onset/early progression from microglial effects on late progression.", "[50] Astrocytic TGFβ1 overproduction worsened SOD1 progression while deactivating protective microglia/T cells; post-onset signaling inhibition extended survival.", "[51] TRIF deficiency shortened SOD1 survival with accumulated abnormal astrocytes; manipulating selected lymphocyte populations did not substantially alter survival.", "[52] Microglial NFκB suppression extended ALS-mouse survival, whereas astrocytic suppression did not rescue motor-neuron death; microglial activation caused death in culture and in vivo.", "[53] NLRP3 or caspase1 loss preserved spatial memory and increased amyloid clearance in APP/PS1, with reduced inflammatory activity and amyloid burden.", "[54] One-month CSF1R inhibition in ten-month 5xFAD removed most microglia and preserved neuronal/spine endpoints and contextual memory without reducing amyloid.", "[63] Normal astrocyte-precursor transplantation in SOD1 rats reduced microgliosis, preserved motor neurons and respiratory/motor function and extended survival, partly through GLT1.", "[64] AraC removal of proliferating CNS cells accelerated SOD1 progression while reducing microglia, progenitors and T cells.", "[66] MyD88-deficient marrow transplantation advanced onset and shortened survival in SOD1-G37R mice relative to competent donor cells.", "[67] Combined IL1a, TNF and C1q knockout extended SOD1-G93A survival and interrogated the proposed microglia-to-reactive-astrocyte pathway.", "[68] Microglial or T-cell depletion blocked tau-model degeneration, while IFNγ or PDCD1 inhibition ameliorated atrophy; human AD tissue contained expanded cytotoxic T cells.", "[69] Trem2 deletion reduced microgliosis and preserved brain volume in PS19 despite similar phosphorylated/insoluble tau." ], "what_would_cross_it": "Independent mediator loss and matched rescue after onset should alter neuron survival and function while retaining normal clearance, peripheral immunity and baseline viability." }, { "subclaim_id": "SC3", "threshold": "Δ", "requirement_quoted": "Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.", "satisfied": "yes", "supporting_evidence": [ "[2] Astrocytic IL-3 programs microglial motility and aggregate clearance and restricts pathology and cognitive decline in tested AD models.", "[4] Parkin loss increased LPS-triggered microglial NLRP3 assembly, motor impairment and dopaminergic loss; Parkin overexpression and HSP90 inhibition interrogated NLRP3 degradation.", "[5] Microglia-specific IL-10 delivery protected dopaminergic neurons in SNCA-overexpressing mice while inducing an activated prophagocytic microglial state and lymphocyte regulation.", "[6] NLY01 reduced dopaminergic loss and behavioral deficits after synuclein fibrils and prolonged survival in A53T mice, associated with reduced neurotoxic astrocyte conversion.", "[7] MCC950 inhibited NLRP3 activity and improved motor, dopamine-neuron and aggregate endpoints in several rodent PD models; degeneration itself could activate the pathway.", "[8] C1q deletion reduced microglial and astrocytic synapse engulfment and restored density in TauP301S; astrocytic engulfment compensated when Trem2-dependent microglial phagocytosis failed.", "[9] A single high-dose systemic LPS or TNF exposure caused sustained brain inflammation and delayed progressive TH-positive nigral-neuron loss, with TNF-receptor comparisons.", "[10] Human iPSC astrocytes reduced neuronal synuclein accumulation and transfer through lysosomal clearance; ATP13A2-deficient astrocytes lost part of this protection.", "[11] Cx3cr1 deficiency worsened AAV-A53T synuclein inflammation and dopaminergic degeneration, while wild-type synuclein injury was similar across receptor genotypes.", "[12] C1q, C3 and CR3 inhibition reduced early amyloid-associated synapse loss; C1q was required for oligomer-induced synaptic and LTP toxicity in the tested models.", "[13] TREM2 deficiency impaired microglial metabolism, and cyclocreatine restored plaque clustering while reducing adjacent neuronal dystrophy.", "[14] Microglial SYK deficiency impaired plaque encasement and worsened pathology and behavior; CLEC7A activation rescued microglial activation in TREM2-R47H mice.", "[15] TREM2-C1q binding restrained complement activation; haploinsufficiency worsened synapse engulfment and a binding peptide rescued synaptic impairment in tested models.", "[16] Nptx2 loss increased C1q-dependent microglial synapse removal, while neuronal Nptx2 overexpression restrained complement and synapse loss in aged tau mice.", "[17] TREM2 loss impaired damage-lipid sensing, microglial plaque clustering and survival and increased amyloid accumulation in 5xFAD.", "[18] Myeloid or microglial LANDO loss increased cytokines and neurotoxic amyloid, with accelerated degeneration, altered signaling and memory deficits.", "[19] Human TREM2-R47H in PS19 reduced microglial reactivity, synapse phagocytosis, atrophy and synapse loss versus the common variant.", "[22] C7 antibody and C6 knockout reduced plaque-adjacent spine/synapse loss in two AD models, implicating terminal complement activity.", "[23] Microglia-selective synuclein overexpression caused dopamine-neuron degeneration without neuronal synuclein aggregation, and oxidative/nitrosative inhibition attenuated damage.", "[24] STING activation preceded dopamine-neuron loss after synuclein fibrils; STING-deficient mice resisted motor, aggregate and neuronal-loss phenotypes.", "[25] Inducible astrocytic APOE4 removal after tau pathology onset reduced neurodegeneration, synapse loss and microglial synaptic phagocytosis.", "[27] Intracerebral clodronate depleted microglia but also damaged vascular integrity, reduced neural markers and increased inflammatory/glial signals; neuronal ATP fell in culture.", "[28] Microglial IL1a, TNF and C1q induced toxic reactive astrocytes; blocking formation protected axotomized neurons, and human disease tissue contained the state.", "[30] Microglial nanotube contacts removed neuronal tau/synuclein aggregates, supplied healthy mitochondria and restored activity; mitochondrial poisoning removed protection.", "[31] NLRP3 loss reduced tau phosphorylation/aggregation, and amyloid-homogenate-induced tau pathology depended on NLRP3; tau itself activated the inflammasome.", "[33] Microglial PD1 deletion increased inflammation and impaired amyloid uptake, with more plaque deposition in APP/PS1.", "[34] ASC specks promoted amyloid cross-seeding after hippocampal delivery, and ASC deficiency or antibody coapplication blocked induced pathology.", "[36] TREM2 knockout worsened tau pathology and degeneration in P301S/APOE4 despite reduced TREM2-dependent microgliosis.", "[45] Heterozygous TBK1 loss advanced SOD1 onset/denervation but reduced late microglial inflammation, slowed progression and extended survival.", "[46] xCT deletion reduced microglial glutamate and inflammatory outputs and slowed late SOD1 degeneration with more surviving motor neurons, despite earlier symptom onset.", "[48] Conditional mutant-SOD1 reduction in astrocytes left onset unchanged but delayed microglial activation and sharply slowed later progression.", "[49] Cell-resolved mutant-SOD1 deletion separated motor-neuron-determined onset/early progression from microglial effects on late progression.", "[50] Astrocytic TGFβ1 overproduction worsened SOD1 progression while deactivating protective microglia/T cells; post-onset signaling inhibition extended survival.", "[51] TRIF deficiency shortened SOD1 survival with accumulated abnormal astrocytes; manipulating selected lymphocyte populations did not substantially alter survival.", "[52] Microglial NFκB suppression extended ALS-mouse survival, whereas astrocytic suppression did not rescue motor-neuron death; microglial activation caused death in culture and in vivo.", "[53] NLRP3 or caspase1 loss preserved spatial memory and increased amyloid clearance in APP/PS1, with reduced inflammatory activity and amyloid burden.", "[54] One-month CSF1R inhibition in ten-month 5xFAD removed most microglia and preserved neuronal/spine endpoints and contextual memory without reducing amyloid.", "[63] Normal astrocyte-precursor transplantation in SOD1 rats reduced microgliosis, preserved motor neurons and respiratory/motor function and extended survival, partly through GLT1.", "[64] AraC removal of proliferating CNS cells accelerated SOD1 progression while reducing microglia, progenitors and T cells.", "[66] MyD88-deficient marrow transplantation advanced onset and shortened survival in SOD1-G37R mice relative to competent donor cells.", "[67] Combined IL1a, TNF and C1q knockout extended SOD1-G93A survival and interrogated the proposed microglia-to-reactive-astrocyte pathway.", "[68] Microglial or T-cell depletion blocked tau-model degeneration, while IFNγ or PDCD1 inhibition ameliorated atrophy; human AD tissue contained expanded cytotoxic T cells.", "[69] Trem2 deletion reduced microgliosis and preserved brain volume in PS19 despite similar phosphorylated/insoluble tau." ], "what_would_cross_it": "" }, { "subclaim_id": "SC3", "threshold": "Ε", "requirement_quoted": "Requires causal support in a defined context, but with clear restriction by subtype, disease stage, model, or tissue.\n\nUse Ε when there is a real causal contribution, but generalization to the entire disease class fails.", "satisfied": "yes", "supporting_evidence": [ "[2] Astrocytic IL-3 programs microglial motility and aggregate clearance and restricts pathology and cognitive decline in tested AD models.", "[4] Parkin loss increased LPS-triggered microglial NLRP3 assembly, motor impairment and dopaminergic loss; Parkin overexpression and HSP90 inhibition interrogated NLRP3 degradation.", "[5] Microglia-specific IL-10 delivery protected dopaminergic neurons in SNCA-overexpressing mice while inducing an activated prophagocytic microglial state and lymphocyte regulation.", "[6] NLY01 reduced dopaminergic loss and behavioral deficits after synuclein fibrils and prolonged survival in A53T mice, associated with reduced neurotoxic astrocyte conversion.", "[7] MCC950 inhibited NLRP3 activity and improved motor, dopamine-neuron and aggregate endpoints in several rodent PD models; degeneration itself could activate the pathway.", "[8] C1q deletion reduced microglial and astrocytic synapse engulfment and restored density in TauP301S; astrocytic engulfment compensated when Trem2-dependent microglial phagocytosis failed.", "[9] A single high-dose systemic LPS or TNF exposure caused sustained brain inflammation and delayed progressive TH-positive nigral-neuron loss, with TNF-receptor comparisons.", "[10] Human iPSC astrocytes reduced neuronal synuclein accumulation and transfer through lysosomal clearance; ATP13A2-deficient astrocytes lost part of this protection.", "[11] Cx3cr1 deficiency worsened AAV-A53T synuclein inflammation and dopaminergic degeneration, while wild-type synuclein injury was similar across receptor genotypes.", "[12] C1q, C3 and CR3 inhibition reduced early amyloid-associated synapse loss; C1q was required for oligomer-induced synaptic and LTP toxicity in the tested models.", "[13] TREM2 deficiency impaired microglial metabolism, and cyclocreatine restored plaque clustering while reducing adjacent neuronal dystrophy.", "[14] Microglial SYK deficiency impaired plaque encasement and worsened pathology and behavior; CLEC7A activation rescued microglial activation in TREM2-R47H mice.", "[15] TREM2-C1q binding restrained complement activation; haploinsufficiency worsened synapse engulfment and a binding peptide rescued synaptic impairment in tested models.", "[16] Nptx2 loss increased C1q-dependent microglial synapse removal, while neuronal Nptx2 overexpression restrained complement and synapse loss in aged tau mice.", "[17] TREM2 loss impaired damage-lipid sensing, microglial plaque clustering and survival and increased amyloid accumulation in 5xFAD.", "[18] Myeloid or microglial LANDO loss increased cytokines and neurotoxic amyloid, with accelerated degeneration, altered signaling and memory deficits.", "[19] Human TREM2-R47H in PS19 reduced microglial reactivity, synapse phagocytosis, atrophy and synapse loss versus the common variant.", "[22] C7 antibody and C6 knockout reduced plaque-adjacent spine/synapse loss in two AD models, implicating terminal complement activity.", "[23] Microglia-selective synuclein overexpression caused dopamine-neuron degeneration without neuronal synuclein aggregation, and oxidative/nitrosative inhibition attenuated damage.", "[24] STING activation preceded dopamine-neuron loss after synuclein fibrils; STING-deficient mice resisted motor, aggregate and neuronal-loss phenotypes.", "[25] Inducible astrocytic APOE4 removal after tau pathology onset reduced neurodegeneration, synapse loss and microglial synaptic phagocytosis.", "[27] Intracerebral clodronate depleted microglia but also damaged vascular integrity, reduced neural markers and increased inflammatory/glial signals; neuronal ATP fell in culture.", "[28] Microglial IL1a, TNF and C1q induced toxic reactive astrocytes; blocking formation protected axotomized neurons, and human disease tissue contained the state.", "[30] Microglial nanotube contacts removed neuronal tau/synuclein aggregates, supplied healthy mitochondria and restored activity; mitochondrial poisoning removed protection.", "[31] NLRP3 loss reduced tau phosphorylation/aggregation, and amyloid-homogenate-induced tau pathology depended on NLRP3; tau itself activated the inflammasome.", "[33] Microglial PD1 deletion increased inflammation and impaired amyloid uptake, with more plaque deposition in APP/PS1.", "[34] ASC specks promoted amyloid cross-seeding after hippocampal delivery, and ASC deficiency or antibody coapplication blocked induced pathology.", "[36] TREM2 knockout worsened tau pathology and degeneration in P301S/APOE4 despite reduced TREM2-dependent microgliosis.", "[45] Heterozygous TBK1 loss advanced SOD1 onset/denervation but reduced late microglial inflammation, slowed progression and extended survival.", "[46] xCT deletion reduced microglial glutamate and inflammatory outputs and slowed late SOD1 degeneration with more surviving motor neurons, despite earlier symptom onset.", "[48] Conditional mutant-SOD1 reduction in astrocytes left onset unchanged but delayed microglial activation and sharply slowed later progression.", "[49] Cell-resolved mutant-SOD1 deletion separated motor-neuron-determined onset/early progression from microglial effects on late progression.", "[50] Astrocytic TGFβ1 overproduction worsened SOD1 progression while deactivating protective microglia/T cells; post-onset signaling inhibition extended survival.", "[51] TRIF deficiency shortened SOD1 survival with accumulated abnormal astrocytes; manipulating selected lymphocyte populations did not substantially alter survival.", "[52] Microglial NFκB suppression extended ALS-mouse survival, whereas astrocytic suppression did not rescue motor-neuron death; microglial activation caused death in culture and in vivo.", "[53] NLRP3 or caspase1 loss preserved spatial memory and increased amyloid clearance in APP/PS1, with reduced inflammatory activity and amyloid burden.", "[54] One-month CSF1R inhibition in ten-month 5xFAD removed most microglia and preserved neuronal/spine endpoints and contextual memory without reducing amyloid.", "[63] Normal astrocyte-precursor transplantation in SOD1 rats reduced microgliosis, preserved motor neurons and respiratory/motor function and extended survival, partly through GLT1.", "[64] AraC removal of proliferating CNS cells accelerated SOD1 progression while reducing microglia, progenitors and T cells.", "[66] MyD88-deficient marrow transplantation advanced onset and shortened survival in SOD1-G37R mice relative to competent donor cells.", "[67] Combined IL1a, TNF and C1q knockout extended SOD1-G93A survival and interrogated the proposed microglia-to-reactive-astrocyte pathway.", "[68] Microglial or T-cell depletion blocked tau-model degeneration, while IFNγ or PDCD1 inhibition ameliorated atrophy; human AD tissue contained expanded cytotoxic T cells.", "[69] Trem2 deletion reduced microgliosis and preserved brain volume in PS19 despite similar phosphorylated/insoluble tau." ], "what_would_cross_it": "" }, { "subclaim_id": "SC3", "threshold": "Ζ", "requirement_quoted": "Requires:\n- Multiple independent causal lines in vivo\n- Replication across at least two relevant systems\n- Narrowing of major alternative models", "satisfied": "no", "supporting_evidence": [ "[2] Astrocytic IL-3 programs microglial motility and aggregate clearance and restricts pathology and cognitive decline in tested AD models.", "[4] Parkin loss increased LPS-triggered microglial NLRP3 assembly, motor impairment and dopaminergic loss; Parkin overexpression and HSP90 inhibition interrogated NLRP3 degradation.", "[5] Microglia-specific IL-10 delivery protected dopaminergic neurons in SNCA-overexpressing mice while inducing an activated prophagocytic microglial state and lymphocyte regulation.", "[6] NLY01 reduced dopaminergic loss and behavioral deficits after synuclein fibrils and prolonged survival in A53T mice, associated with reduced neurotoxic astrocyte conversion.", "[7] MCC950 inhibited NLRP3 activity and improved motor, dopamine-neuron and aggregate endpoints in several rodent PD models; degeneration itself could activate the pathway.", "[8] C1q deletion reduced microglial and astrocytic synapse engulfment and restored density in TauP301S; astrocytic engulfment compensated when Trem2-dependent microglial phagocytosis failed.", "[9] A single high-dose systemic LPS or TNF exposure caused sustained brain inflammation and delayed progressive TH-positive nigral-neuron loss, with TNF-receptor comparisons.", "[10] Human iPSC astrocytes reduced neuronal synuclein accumulation and transfer through lysosomal clearance; ATP13A2-deficient astrocytes lost part of this protection.", "[11] Cx3cr1 deficiency worsened AAV-A53T synuclein inflammation and dopaminergic degeneration, while wild-type synuclein injury was similar across receptor genotypes.", "[12] C1q, C3 and CR3 inhibition reduced early amyloid-associated synapse loss; C1q was required for oligomer-induced synaptic and LTP toxicity in the tested models.", "[13] TREM2 deficiency impaired microglial metabolism, and cyclocreatine restored plaque clustering while reducing adjacent neuronal dystrophy.", "[14] Microglial SYK deficiency impaired plaque encasement and worsened pathology and behavior; CLEC7A activation rescued microglial activation in TREM2-R47H mice.", "[15] TREM2-C1q binding restrained complement activation; haploinsufficiency worsened synapse engulfment and a binding peptide rescued synaptic impairment in tested models.", "[16] Nptx2 loss increased C1q-dependent microglial synapse removal, while neuronal Nptx2 overexpression restrained complement and synapse loss in aged tau mice.", "[17] TREM2 loss impaired damage-lipid sensing, microglial plaque clustering and survival and increased amyloid accumulation in 5xFAD.", "[18] Myeloid or microglial LANDO loss increased cytokines and neurotoxic amyloid, with accelerated degeneration, altered signaling and memory deficits.", "[19] Human TREM2-R47H in PS19 reduced microglial reactivity, synapse phagocytosis, atrophy and synapse loss versus the common variant.", "[22] C7 antibody and C6 knockout reduced plaque-adjacent spine/synapse loss in two AD models, implicating terminal complement activity.", "[23] Microglia-selective synuclein overexpression caused dopamine-neuron degeneration without neuronal synuclein aggregation, and oxidative/nitrosative inhibition attenuated damage.", "[24] STING activation preceded dopamine-neuron loss after synuclein fibrils; STING-deficient mice resisted motor, aggregate and neuronal-loss phenotypes.", "[25] Inducible astrocytic APOE4 removal after tau pathology onset reduced neurodegeneration, synapse loss and microglial synaptic phagocytosis.", "[27] Intracerebral clodronate depleted microglia but also damaged vascular integrity, reduced neural markers and increased inflammatory/glial signals; neuronal ATP fell in culture.", "[28] Microglial IL1a, TNF and C1q induced toxic reactive astrocytes; blocking formation protected axotomized neurons, and human disease tissue contained the state.", "[30] Microglial nanotube contacts removed neuronal tau/synuclein aggregates, supplied healthy mitochondria and restored activity; mitochondrial poisoning removed protection.", "[31] NLRP3 loss reduced tau phosphorylation/aggregation, and amyloid-homogenate-induced tau pathology depended on NLRP3; tau itself activated the inflammasome.", "[33] Microglial PD1 deletion increased inflammation and impaired amyloid uptake, with more plaque deposition in APP/PS1.", "[34] ASC specks promoted amyloid cross-seeding after hippocampal delivery, and ASC deficiency or antibody coapplication blocked induced pathology.", "[36] TREM2 knockout worsened tau pathology and degeneration in P301S/APOE4 despite reduced TREM2-dependent microgliosis.", "[45] Heterozygous TBK1 loss advanced SOD1 onset/denervation but reduced late microglial inflammation, slowed progression and extended survival.", "[46] xCT deletion reduced microglial glutamate and inflammatory outputs and slowed late SOD1 degeneration with more surviving motor neurons, despite earlier symptom onset.", "[48] Conditional mutant-SOD1 reduction in astrocytes left onset unchanged but delayed microglial activation and sharply slowed later progression.", "[49] Cell-resolved mutant-SOD1 deletion separated motor-neuron-determined onset/early progression from microglial effects on late progression.", "[50] Astrocytic TGFβ1 overproduction worsened SOD1 progression while deactivating protective microglia/T cells; post-onset signaling inhibition extended survival.", "[51] TRIF deficiency shortened SOD1 survival with accumulated abnormal astrocytes; manipulating selected lymphocyte populations did not substantially alter survival.", "[52] Microglial NFκB suppression extended ALS-mouse survival, whereas astrocytic suppression did not rescue motor-neuron death; microglial activation caused death in culture and in vivo.", "[53] NLRP3 or caspase1 loss preserved spatial memory and increased amyloid clearance in APP/PS1, with reduced inflammatory activity and amyloid burden.", "[54] One-month CSF1R inhibition in ten-month 5xFAD removed most microglia and preserved neuronal/spine endpoints and contextual memory without reducing amyloid.", "[63] Normal astrocyte-precursor transplantation in SOD1 rats reduced microgliosis, preserved motor neurons and respiratory/motor function and extended survival, partly through GLT1.", "[64] AraC removal of proliferating CNS cells accelerated SOD1 progression while reducing microglia, progenitors and T cells.", "[66] MyD88-deficient marrow transplantation advanced onset and shortened survival in SOD1-G37R mice relative to competent donor cells.", "[67] Combined IL1a, TNF and C1q knockout extended SOD1-G93A survival and interrogated the proposed microglia-to-reactive-astrocyte pathway.", "[68] Microglial or T-cell depletion blocked tau-model degeneration, while IFNγ or PDCD1 inhibition ameliorated atrophy; human AD tissue contained expanded cytotoxic T cells.", "[69] Trem2 deletion reduced microgliosis and preserved brain volume in PS19 despite similar phosphorylated/insoluble tau." ], "what_would_cross_it": "Bidirectional, stage-controlled mediator experiments should distinguish causal amplification from passive response while matching the initiating injury; initiation is not required for amplification." }, { "subclaim_id": "SC4", "threshold": "Δ", "requirement_quoted": "Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.", "satisfied": "no", "supporting_evidence": [ "[20] Open-label NT-0796 in ten PD participants for 28 days showed CSF exposure and reduced inflammatory markers, with four healthy volunteers also studied.", "[35] AL002c stimulated microglial proliferation and reduced filamentous plaques and neurite dystrophy in a human-TREM2 AD model; first-human fluid engagement was also reported.", "[37] INVOKE1 in 64 healthy volunteers showed AL002 CSF penetration, soluble-TREM2 reduction and signaling/recruitment biomarker increases with acceptable single-dose tolerability.", "[38] The AD-protective PLCG2-P522R knock-in increased enzyme activity, macrophage survival/acute responses and measures of microglial function.", "[44] A 20-person randomized PD phase1 study reported modest short-term motor improvement with sargramostim, peripheral Treg changes and substantial adverse-event burden.", "[61] A 40-person randomized AD study found short-term MMSE improvement after three weeks of sargramostim, with peripheral immune and plasma biomarker changes." ], "what_would_cross_it": "Prespecified human cell-state target engagement and sustained clinical trajectory changes, together with independent causal replications in AD, PD and ALS, would cross the generalization gate." } ], "generalization_check": { "generalization_tested": "yes", "context_boundary_mapped": "yes", "internal_negative_controls": [ "Neuron versus astrocyte/microglia SOD1 removal separates onset from progression.", "Astrocyte NFκB inhibition is ineffective where microglial-lineage inhibition is effective.", "APOE3 versus APOE4 and Cre-negative tamoxifen controls.", "Protective SYK loss reduces activation while worsening injury.", "Complement deletion is null in some ALS/PD settings despite positive AD synaptic experiments.", "RIPK3/MLKL culture rescue versus organismal null.", "AL002 target engagement versus clinical null and ARIA.", "Minocycline accelerates ALS functional decline despite a proposed anti-inflammatory mechanism." ], "note": "The map spans amyloid and nonamyloid AD models, tau/APOE settings, toxin/seeded PD, SOD1 ALS, early and late intervention, and human trials. Opposite TREM2, complement and immune-state effects are mapped before claiming generality. Biomarkers and astrocyte activation markers are not interchangeable with neuron loss. Neither late human failures nor engineered successes alone decide the entire disease class." }, "falsification_patterns_met": [ { "pattern": "Activation can protect as well as injure", "evidence": "SYK/TREM2/IL3 and TRIF/MyD88 loss can worsen pathology or outcome; reduced activation is not uniformly protective.", "downgrade_applied": false }, { "pattern": "Causal amplification need not prevent onset", "evidence": "Boillee, Yamanaka, Frakes and Guttenplan change later progression with little or no onset effect.", "downgrade_applied": false }, { "pattern": "Clinical engagement does not guarantee trajectory benefit", "evidence": "AL002 CSF engagement accompanies a clinical null; minocycline worsens ALSFRS-R decline; short sargramostim signals are mixed.", "downgrade_applied": false } ], "pitfalls_flagged": [ { "pitfall": "Reactive and causal treated as mutually exclusive", "where": "Original causal-driver wording and SOD1 timing experiments." }, { "pitfall": "Activation treated as one uniform harmful state", "where": "TREM2/SYK/IL3 and protective immune programs." }, { "pitfall": "Provider retrieval failure treated as missing clinical literature", "where": "Consensus did not retrieve named trials; original PubMed reports were examined." }, { "pitfall": "Short MMSE signal presented as established benefit", "where": "Sargramostim baseline imbalance, ADAS-Cog13 worsening and null functional endpoints." }, { "pitfall": "Historical score presented as blinded derivation", "where": "Historical tau/neuro Γ levels were visible before new adjudication; explicitly unblinded." } ], "causal_tally_audit": { "tally_claimed_by_document": 50, "tally_after_audit": 50, "items_rejected": [ "Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines.", "Shared cohorts, experimental platforms, transgenic lineages and repeated outcomes do not constitute fully independent causal lines." ] }, "steelman": { "case_one_rung_higher": "The strongest Δ/Ε case assembles cell-lineage SOD1, partial NFκB, astrocytic APOE4 and cytokine deletion with neuronal survival and functional outcomes, plus human risk genetics. It convincingly crosses causal contribution in defined contexts. It does not establish one harmful activation exposure throughout AD, PD and ALS or sustained selective human clinical mediation.", "case_one_rung_lower": "The strongest Β case treats all activation as correlated response to injured neurons. That fails against progression-changing lineage perturbations and matched controls. Reactive causal amplification is experimentally supported and deserves Ε for the defined subclaims; Γ for the full conjunction reflects the unresolved generalization gate.", "which_rejected": "Reject a passive-bystander-only account, retain defined causal amplification, and reserve stronger disease-class grades for prospective state-specific generalization. Do not lower the score merely because the glial response follows an initiating injury.", "blocking_cap_threshold_or_missing_experiment": "Missing experiment: Induce loss of a prespecified harmful glial program after comparable neuronal pathology begins, preserve protective clearance and peripheral immune function, then restore the same mediator with cell-specific rescue in independent AD, PD and ALS settings." }, "final_score": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "69 primary reports with 6 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.", "rests_on_non_peer_reviewed_work": false, "rationale": "The registered weakest-link conjunction returns Γ because disease-class human generalization remains unresolved. Defined glial states have real causal effects on neuronal loss and progression, including reactive amplifiers. This evidence is not dismissed for being downstream. Opposite effects of protective immune programs and negative or harmful human interventions prevent treating chronic activation as one broadly pathogenic exposure. The limiting gate is generalization and state-specific human mediation, not an added obligation to initiate disease." }, "role_of_mechanism": { "classification": "reinforcing / stabilizing factor", "derivation_step_matched": 5, "derivation": "Defined glial and immune states causally amplify established disease. The original neuronal lesion can precede their harmful contribution, so reactive origin does not imply noncausality. Protective states can oppose injury. This conditional amplification is supported more directly than a general initiating or rate-limiting role.", "tournament_used_as_tiebreaker": false, "note": "Derived from causal direction, not tournament rank." }, "extended_scoring_MSD": { "momentum": { "value": "Mechanistic only", "artifact": "Completed 2026 AL002 and AZA-PD reports and recent state-selective models refine the clinical and protective-state boundary. No pending decisive result is claimed.", "justification": "Completed 2026 AL002 and AZA-PD reports and recent state-selective models refine the clinical and protective-state boundary. No pending decisive result is claimed." }, "stability": { "value": "Stable", "trigger": "No verified pending report is asserted as likely to change the registered broad level imminently.", "justification": "No verified pending report is asserted as likely to change the registered broad level imminently." }, "divergence": { "implied_level": null, "implied_level_basis": "No single field-implied level is defensible from conflicting framings.", "assessed_level": "Γ", "gap_in_rungs": null, "value": "Contested", "justification": "No manufactured field consensus or arithmetic gap." }, "calibration_note": "M/S/D never modify HSEF level or confidence." }, "change_record": { "applies": false, "prior_level": "Editorial category and historical Γ tau/neuro levels were visible in memory before fresh adjudication. This review is unblinded; historical levels were not adopted as score targets.", "prior_confidence": null, "prior_source": null, "derived_before_consulting_prior": false, "new_level": "Γ", "direction": "newly assigned", "what_moved_it": "Fresh primary evidence appraisal; not blinded.", "divergence_from_other_reviewers": null }, "proposed_decisive_experiments": [ { "name": "Registered boundary experiment", "experiment": "Induce loss of a prespecified harmful glial program after comparable neuronal pathology begins, preserve protective clearance and peripheral immune function, then restore the same mediator with cell-specific rescue in independent AD, PD and ALS settings.", "readout": "Blinded neuron counts, functional decline, survival where relevant, and direct cell-state/target engagement", "critical_control": "Matched initiating protein burden, stage, neuronal viability, clearance, peripheral immunity and rescue expression", "supporting_result": "Post-onset suppression slows loss and functional decline; matched rescue restores both with replicated prespecified state boundaries", "falsifying_result": "Verified selective loss leaves degeneration unchanged, or protection is explained wholly by altered initial protein burden or nonspecific immune effects" } ], "knowledge_gaps": [ { "name": "Gap 1", "statement": "Define harmful and protective microglial/astrocytic states prospectively rather than assigning labels after outcome.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 2", "statement": "Use post-onset selective loss and matched rescue to separate initiation, amplification and recovery.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 3", "statement": "Match initiating protein burden and intrinsic neuronal toxicity so aggregate lowering does not masquerade as glial mediation.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 4", "statement": "Verify human cell-state engagement and sustained functional outcomes, preserving null and harmful results alongside positive biomarkers.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 5", "statement": "Map amyloid, tau, APOE, TREM2 and disease-stage boundaries of protective clearance before targeting activation broadly.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 6", "statement": "Resolve peripheral adaptive-immune contributions and systemic drug effects separately from CNS glial mediation.", "relevance": "Limits mechanism identification or scope." } ], "review_metadata": { "review_date": "2026-10-06", "reviewer": "Codex", "evidence_base_note": "69 primary reports; literature cutoff 2026-10-06; source examination UTC date 2026-10-06; bounded critical review, not exhaustive systematic review.", "literature_tools_available": true, "literature_tools_note": "Life Sciences Literature PubMed/Entrez; attempted Europe PMC XML and successful public NCBI PMC direct HTTPS access are separately logged. Signed-in Consensus browser discovery and targeted indexed full-text checks are reconciled with original sections; failed matches and source substitutions remain explicit. Zero Consensus API calls.", "skill_version": "5.3", "validator_run": "exact archived v5.3 validator 2.3; see validator.txt", "validator_warnings_addressed": "Phenomenon entry was restated as the preregistered causal claim. No real phenomenon is labelled refuted; warning is explicitly justified.", "consensus_consistency_audit": "2026-10-09; supplementary provenance/source reconciliation; original grading retained; prior grades visible." }, "is_calibration_entry": { "value": false, "entry_role": "not_calibration", "blind_graded": null, "completed_blinded_calibration": false, "expected_band_sealed_at": "", "target_sha256": "", "target_authorship": "not applicable", "target_author_saw_review": null, "future_run_status": "not prepared", "unblinded_reason": "Ranking categorical verdict and index guidance were visible. No completed blinded calibration claimed." }, "upper_ladder_check": { "final_level_below_zeta": true, "equivalents_considered": [ { "kind": "mendelian_randomization", "available": false, "why_not_sufficient": "TREM2/PLCG2/ABI3 risk genetics and randomized clinical immune interventions were considered. Genetics has directional and functional heterogeneity; AL002 has CSF engagement but a clinical null, and broad drugs have uncertain glial specificity. These data do not establish a universal mediator-to-clinical trajectory chain. Higher grades remain available to prospectively defined states with convergent causal human and model evidence." }, { "kind": "natural_experiment", "available": true, "why_not_sufficient": "TREM2/PLCG2/ABI3 risk genetics and randomized clinical immune interventions were considered. Genetics has directional and functional heterogeneity; AL002 has CSF engagement but a clinical null, and broad drugs have uncertain glial specificity. These data do not establish a universal mediator-to-clinical trajectory chain. Higher grades remain available to prospectively defined states with convergent causal human and model evidence." }, { "kind": "dose_response_across_populations", "available": false, "why_not_sufficient": "TREM2/PLCG2/ABI3 risk genetics and randomized clinical immune interventions were considered. Genetics has directional and functional heterogeneity; AL002 has CSF engagement but a clinical null, and broad drugs have uncertain glial specificity. These data do not establish a universal mediator-to-clinical trajectory chain. Higher grades remain available to prospectively defined states with convergent causal human and model evidence." }, { "kind": "withdrawal_rechallenge", "available": false, "why_not_sufficient": "TREM2/PLCG2/ABI3 risk genetics and randomized clinical immune interventions were considered. Genetics has directional and functional heterogeneity; AL002 has CSF engagement but a clinical null, and broad drugs have uncertain glial specificity. These data do not establish a universal mediator-to-clinical trajectory chain. Higher grades remain available to prospectively defined states with convergent causal human and model evidence." }, { "kind": "therapeutic_perturbation_hard_endpoint", "available": true, "why_not_sufficient": "TREM2/PLCG2/ABI3 risk genetics and randomized clinical immune interventions were considered. Genetics has directional and functional heterogeneity; AL002 has CSF engagement but a clinical null, and broad drugs have uncertain glial specificity. These data do not establish a universal mediator-to-clinical trajectory chain. Higher grades remain available to prospectively defined states with convergent causal human and model evidence." } ], "convergence_present": true, "cap_reapplied_to_convergent_set": false }, "provenance_header": { "sources_total": 69, "claims_total": 74, "claims_verified": 74, "claims_unverified": 0, "claims_contradicted": 0, "tier_a_sources": 69, "generated_by": "Codex; HSEF v5.3", "gate_passed": true }, "claims": [ { "id": "C1", "text": "Single-nucleus profiles of six PD and five control midbrains identified activated microglial and astrocytic states alongside a dysfunctional neuronal cluster. Postmortem states and risk enrichment do not identify initiating direction or glial necessity; the central-mechanism language exceeds selective intervention.", "carries_number": false, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 1 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C2", "text": "Astrocytic IL-3 programs microglial motility and aggregate clearance and restricts pathology and cognitive decline in tested AD models. Protective activation contradicts treating activation as uniformly toxic; constitutive cytokine and model backgrounds limit natural human mediation.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 2 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C3", "text": "An 84-donor multimodal atlas reconstructed an early phase with inflammatory glia and selective inhibitory-neuron loss before broader later neuronal loss. Pseudoprogression is cross-sectional reconstructed time, not repeated donor observation; early glia already coexist with pathology and cell loss. UpdateOf is a preceding preprint.", "carries_number": true, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 3 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C4", "text": "Parkin loss increased LPS-triggered microglial NLRP3 assembly, motor impairment and dopaminergic loss; Parkin overexpression and HSP90 inhibition interrogated NLRP3 degradation. Global Parkin deletion, imposed systemic LPS and broad HSP90 effects do not isolate a microglial-only natural PD initiator.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 4 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C5", "text": "Microglia-specific IL-10 delivery protected dopaminergic neurons in SNCA-overexpressing mice while inducing an activated prophagocytic microglial state and lymphocyte regulation. Activation remains present in a protective state; local cytokine effects extend beyond microglia, and imposed SNCA expression restricts scope.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 5 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C6", "text": "NLY01 reduced dopaminergic loss and behavioral deficits after synuclein fibrils and prolonged survival in A53T mice, associated with reduced neurotoxic astrocyte conversion. GLP1R agonism and forced/transgenic proteinopathy do not establish selective glial mediation or human efficacy; the clinical trial is assessed separately.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 6 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C7", "text": "MCC950 inhibited NLRP3 activity and improved motor, dopamine-neuron and aggregate endpoints in several rodent PD models; degeneration itself could activate the pathway. This supports an injury-triggered causal amplifier, not obligatory inflammation-first origin; drug/pathway and induced-model scope must be retained.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 7 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C8", "text": "C1q deletion reduced microglial and astrocytic synapse engulfment and restored density in TauP301S; astrocytic engulfment compensated when Trem2-dependent microglial phagocytosis failed. Synapse density is not total neuronal survival, and global complement deletion affects multiple functions and engineered backgrounds.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 8 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C9", "text": "A single high-dose systemic LPS or TNF exposure caused sustained brain inflammation and delayed progressive TH-positive nigral-neuron loss, with TNF-receptor comparisons. The imposed systemic inflammatory insult and receptor-wide deletion do not establish native chronic glial primacy; TH loss is not an audited all-neuron count.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 9 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C10", "text": "Human iPSC astrocytes reduced neuronal synuclein accumulation and transfer through lysosomal clearance; ATP13A2-deficient astrocytes lost part of this protection. Protective glial function is demonstrated in culture, not intact organismal progression or a general absence of harmful glial states.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 10 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C11", "text": "Cx3cr1 deficiency worsened AAV-A53T synuclein inflammation and dopaminergic degeneration, while wild-type synuclein injury was similar across receptor genotypes. Receptor loss can remove restraint rather than simply reduce activation; developmental and mutant-expression contexts limit broad extrapolation.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 11 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C12", "text": "C1q, C3 and CR3 inhibition reduced early amyloid-associated synapse loss; C1q was required for oligomer-induced synaptic and LTP toxicity in the tested models. Early means before overt plaques, not before all amyloid or neuronal stress; complementary pathway controls support conditional mediation without proving human initiation.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 12 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C13", "text": "TREM2 deficiency impaired microglial metabolism, and cyclocreatine restored plaque clustering while reducing adjacent neuronal dystrophy. A protective energetic/clearance program can be activated; metabolic rescue is broader than a single inflammatory mediator and occurs in amyloid-model scope.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 13 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C14", "text": "Microglial SYK deficiency impaired plaque encasement and worsened pathology and behavior; CLEC7A activation rescued microglial activation in TREM2-R47H mice. Different activated programmes have different effects; antibody rescue of activation is not independently established complete human clinical rescue. Original Results: inducible SYK deletion lowers plaque-associated microgliosis but increases Aβ, neuritic dystrophy and memory impairment. Monocytes recover after washout; border-associated macrophages retain partial deletion. Late deletion also impairs clustering. CLEC7A rescue restores uptake and plaque morphology, not demonstrated long-term behavioral rescue.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 14 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph0, 1:RESULTS:paragraph2, 1:RESULTS:paragraph3, 1:RESULTS:paragraph6, 1:RESULTS:paragraph14. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C15", "text": "TREM2-C1q binding restrained complement activation; haploinsufficiency worsened synapse engulfment and a binding peptide rescued synaptic impairment in tested models. Human tissue complex associations do not establish causal direction; complement-restraint protection is distinct from globally harmful activation.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 15 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C16", "text": "Nptx2 loss increased C1q-dependent microglial synapse removal, while neuronal Nptx2 overexpression restrained complement and synapse loss in aged tau mice. The initiating alteration is neuronal complement restraint and one rescue uses AAV overexpression; synapse preservation is not whole-disease neuronal survival.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 16 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C17", "text": "TREM2 loss impaired damage-lipid sensing, microglial plaque clustering and survival and increased amyloid accumulation in 5xFAD. Protective immune responsiveness is demonstrated in an amyloid context; amyloid load alone does not establish cognitive/neuron-loss mediation or chronic-state universality.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 17 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C18", "text": "Myeloid or microglial LANDO loss increased cytokines and neurotoxic amyloid, with accelerated degeneration, altered signaling and memory deficits. Loss of aggregate clearance may precede harmful inflammation, so pure inflammatory primacy is not isolated; a linked correction remains qualified.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 18 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C19", "text": "Human TREM2-R47H in PS19 reduced microglial reactivity, synapse phagocytosis, atrophy and synapse loss versus the common variant. An AD-risk allele is protective in this tau-only model, mapping upstream substrate/stage context rather than proving uniform effects in natural AD.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 19 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C20", "text": "Open-label NT-0796 in ten PD participants for 28 days showed CSF exposure and reduced inflammatory markers, with four healthy volunteers also studied. Short safety/pharmacokinetic biomarker engagement without randomized clinical trajectory is not disease modification or evidence of a glial initiating event.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 20 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C21", "text": "C3 deficiency did not preserve dopamine-neuron/fiber or dopamine-metabolite endpoints after acute or chronic MPTP exposure. This null constrains complement C3 in a toxin context, not every immune mediator; the linked notice corrects an author name.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 21 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C22", "text": "C7 antibody and C6 knockout reduced plaque-adjacent spine/synapse loss in two AD models, implicating terminal complement activity. Synapse endpoints are not audited neuron-survival/function trajectories, and constitutive knockout or systemic antibody may affect other compartments.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 22 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C23", "text": "Microglia-selective synuclein overexpression caused dopamine-neuron degeneration without neuronal synuclein aggregation, and oxidative/nitrosative inhibition attenuated damage. A strong imposed glial sufficiency setting is not physiological endogenous primacy; peripheral recruitment and broad oxidative inhibition remain alternative mediators. Linked correction qualified.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 23 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C24", "text": "STING activation preceded dopamine-neuron loss after synuclein fibrils; STING-deficient mice resisted motor, aggregate and neuronal-loss phenotypes. Global STING deficiency and imposed fibrils constrain cell specificity and natural initiation; human staining is correlational.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 24 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C25", "text": "Inducible astrocytic APOE4 removal after tau pathology onset reduced neurodegeneration, synapse loss and microglial synaptic phagocytosis. Post-onset protection supports causal amplification; APOE affects lipid and tau pathways in addition to inflammation, and the P301S/APOE context remains explicit. Original Results: astrocytic APOE deletion at 5.5 months after initial tau pathology protects APOE4 but not APOE3 mice from atrophy. Tamoxifen-treated Cre-negative controls exclude tamoxifen alone; NfL, nest building and synaptic measures improve. APOE influences lipid handling and tau pathology as well as inflammatory states, so the mediation is not inflammation-selective.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 25 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph0, 1:RESULTS:paragraph1, 1:RESULTS:paragraph2, 1:RESULTS:paragraph15. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C26", "text": "Microscopy in APP/PS1 and human AD tissue showed reactive astrocytes engulfing presynaptic dystrophies, with a low fraction of total dystrophies cleared. Reactive phagocytosis may clear damage rather than kill viable synapses; proposed protection is not tested by this static study.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 26 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C27", "text": "Intracerebral clodronate depleted microglia but also damaged vascular integrity, reduced neural markers and increased inflammatory/glial signals; neuronal ATP fell in culture. This methodological perturbation exposes depletion off-target confounding, rather than showing that all microglia protect in AD, PD or ALS.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 27 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C28", "text": "Microglial IL1a, TNF and C1q induced toxic reactive astrocytes; blocking formation protected axotomized neurons, and human disease tissue contained the state. Injury precedes the causal astrocyte response in the in-vivo test; human postmortem abundance and a marker class do not establish obligatory inflammation-first disease origin.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 28 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C29", "text": "Single-cell mapping and Trem2 loss separated two disease-associated microglial activation phases, with intracellular amyloid in mapped cells. Potential protective function is not a selective hard-outcome rescue in this abstract; the DAM name is not a causal toxicity classification.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 29 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C30", "text": "Microglial nanotube contacts removed neuronal tau/synuclein aggregates, supplied healthy mitochondria and restored activity; mitochondrial poisoning removed protection. Broad mitochondrial perturbation and culture-based transfer do not establish organismal disease trajectory; aggregate transfer can be protective rather than uniformly toxic.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 30 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C31", "text": "NLRP3 loss reduced tau phosphorylation/aggregation, and amyloid-homogenate-induced tau pathology depended on NLRP3; tau itself activated the inflammasome. The test supports a bidirectional proteinopathy-immune pathway, with imposed initiation and pathology endpoints rather than a complete human survival dependency.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 31 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C32", "text": "In 211 cognitively unimpaired people, glial fluid markers were elevated in preclinical AD and structural-equation relations linked them with amyloid, tau and injury markers. Statistical arrows and biomarker mediation do not establish causal intervention or true temporal lineage; normal cognition does not mean absence of primary protein pathology.", "carries_number": true, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 32 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C33", "text": "Microglial PD1 deletion increased inflammation and impaired amyloid uptake, with more plaque deposition in APP/PS1. Loss of immune restraint and clearance is harmful in this context; plaque load is not independently demonstrated neuron loss or general inflammatory primacy.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 33 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C34", "text": "ASC specks promoted amyloid cross-seeding after hippocampal delivery, and ASC deficiency or antibody coapplication blocked induced pathology. Forced amyloid/speck entry and aggregate endpoints establish inflammatory seeding capability, not native disease initiation or clinical benefit.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 34 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C35", "text": "AL002c stimulated microglial proliferation and reduced filamentous plaques and neurite dystrophy in a human-TREM2 AD model; first-human fluid engagement was also reported. Activation can be protective in this model, and phase1 engagement is not human clinical efficacy; later reports overlap the clinical programme.", "carries_number": true, "load_bearing_for": [ "SC2", "SC4" ], "source_ns": [ 35 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C36", "text": "TREM2 knockout worsened tau pathology and degeneration in P301S/APOE4 despite reduced TREM2-dependent microgliosis. This reverses the earlier mouse-Apoe tau-only protection contrast, showing genotype and residual microglial state matter more than bulk activation reduction.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 36 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C37", "text": "INVOKE1 in 64 healthy volunteers showed AL002 CSF penetration, soluble-TREM2 reduction and signaling/recruitment biomarker increases with acceptable single-dose tolerability. Healthy phase1 safety and engagement cannot establish AD trajectory benefit; the 2020 programme report is not independent efficacy evidence.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 37 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C38", "text": "The AD-protective PLCG2-P522R knock-in increased enzyme activity, macrophage survival/acute responses and measures of microglial function. Protective genetic association is from a separate study; cell function and PET signals do not prove chronic harmful activation or disease rescue in this KI experiment.", "carries_number": true, "load_bearing_for": [ "SC2", "SC4" ], "source_ns": [ 38 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C39", "text": "In 412 randomized ALS patients, minocycline accelerated the prespecified ALSFRS-R decline compared with placebo over nine months. Broad drug pharmacology and unverified selective glial engagement mean this refutes the tested treatment expectation, not all inflammatory causal contribution; mortality worsening was nonsignificant.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 39 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C40", "text": "INVOKE2 randomized 381 early-AD participants and found no CDR-SB benefit despite sustained central TREM2 engagement/signaling biomarkers; ARIA-like MRI events were prominent. TREM2 agonism in symptomatic AD is a specific strategy; fluid engagement does not prove adequate state-specific glial rescue, and a clinical null does not eliminate all immune causality.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 40 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C41", "text": "Two phase3 semaglutide trials randomized 3808 early-AD participants and showed no slowing of 104-week CDR-SB progression. GLP1R agonism is systemic and pleiotropic, without verified selective glial engagement here; this constrains broad drug translation rather than isolating a glial mechanism.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 41 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C42", "text": "NLY01 randomized 255 early untreated PD participants and showed no 36-week motor/ADL primary endpoint benefit at either dose, with frequent gastrointestinal events. Exploratory younger-patient signals are not confirmatory; human microglial-state inhibition was not verified by this abstract, so null treatment efficacy is not complete mediator removal.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 42 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C43", "text": "AZA-PD randomized 66 early PD participants and did not improve the prespecified 12-month off-state gait-axial endpoint; exploratory immune and sex-specific findings were reported. Peripheral broad immunosuppression is not cell-state-selective glial blockade, and subgroup signals require replication; clinical null constrains the tested strategy.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 43 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C44", "text": "A 20-person randomized PD phase1 study reported modest short-term motor improvement with sargramostim, peripheral Treg changes and substantial adverse-event burden. Safety-focused small enrollment, short exposure and peripheral modulation do not establish sustained neuroprotection or prove a CNS glial mediator.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 44 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C45", "text": "Heterozygous TBK1 loss advanced SOD1 onset/denervation but reduced late microglial inflammation, slowed progression and extended survival. Global pleiotropic autophagy/immune effects show stage-dependent direction, rather than a universal beneficial inflammatory suppression or native sporadic ALS cause.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 45 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C46", "text": "xCT deletion reduced microglial glutamate and inflammatory outputs and slowed late SOD1 degeneration with more surviving motor neurons, despite earlier symptom onset. Global antiporter deletion and redox effects complicate microglial specificity; onset and progression move in opposite directions.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 46 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C47", "text": "C1q or C3 loss did not change SOD1 disease onset/progression; C1q deletion enhanced rather than prevented loss of certain motor-neuron synaptic inputs. Complement activation can be a correlate without disease-course necessity in this setting; null single mediators do not disprove all glial contributions.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 47 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C48", "text": "Conditional mutant-SOD1 reduction in astrocytes left onset unchanged but delayed microglial activation and sharply slowed later progression. This is direct cell-resolved causal amplification in familial SOD1 models, not proof of inflammation-first initiation or every reactive astrocyte being toxic.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 48 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C49", "text": "Cell-resolved mutant-SOD1 deletion separated motor-neuron-determined onset/early progression from microglial effects on late progression. Different disease phases and engineered familial mutation define scope; reducing mutant protein may restore several glial functions beyond inflammation.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 49 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C50", "text": "Astrocytic TGFβ1 overproduction worsened SOD1 progression while deactivating protective microglia/T cells; post-onset signaling inhibition extended survival. Reducing one cytokine can improve protective immune activity rather than uniformly suppress activation; source overproduction and drug pleiotropy remain limits.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 50 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C51", "text": "TRIF deficiency shortened SOD1 survival with accumulated abnormal astrocytes; manipulating selected lymphocyte populations did not substantially alter survival. Innate signaling can protect the motor-neuron environment, and cell correlations do not by themselves prove which abnormal astrocyte state mediates the whole effect.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 51 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C52", "text": "Microglial NFκB suppression extended ALS-mouse survival, whereas astrocytic suppression did not rescue motor-neuron death; microglial activation caused death in culture and in vivo. The endogenous pathway perturbation is cell-resolved, but forced constitutive activation and SOD1 genotype restrict broad human or inflammation-first inference. Original Results: CSF1R-Cre acts in the mononuclear phagocyte lineage, although spinal reporter staining is restricted to microglia. Homozygous IKKβ deletion caused serious immune dysfunction, so survival was assessed in heterozygotes. Median survival rose from 133 to 153 days, onset was unchanged, and mutant SOD1 abundance was unchanged. Forced NFκB activation also kills neurons, but is not physiological initiation.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 52 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph8, 1:RESULTS:paragraph9, 1:RESULTS:paragraph12, 1:RESULTS:paragraph13. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C53", "text": "NLRP3 or caspase1 loss preserved spatial memory and increased amyloid clearance in APP/PS1, with reduced inflammatory activity and amyloid burden. Constitutive global immune loss and familial amyloid background are limited scopes; downstream response to amyloid can still mediate causal decline.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 53 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C54", "text": "One-month CSF1R inhibition in ten-month 5xFAD removed most microglia and preserved neuronal/spine endpoints and contextual memory without reducing amyloid. This is a post-pathology causal contribution; systemic receptor pharmacology and total-cell removal are broader than a single harmful state, and protective contexts elsewhere remain.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 54 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C55", "text": "Original discovery and replication genotyping plus GWAS meta-analysis linked rare TREM2 variants to AD risk. This is a primary genetic cohort report despite its meta-analysis component; genetic immune dysfunction does not identify uniformly harmful chronic activation or a specific inflammatory mediator.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 55 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C56", "text": "Icelandic sequencing/imputation and international replication associated TREM2-R47H with about threefold AD risk and poorer cognition in unaffected elderly carriers. The variant's immune/clearance mechanism needs separate functional identification; protective microglial failure is as relevant as excess inflammation, and replication cohorts may overlap other reports.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 56 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C57", "text": "Three-stage genotyping in 85133 participants identified protective PLCG2-P522R and risk-increasing ABI3/TREM2 coding variants enriched in microglial pathways. The genetic evidence supports immune-function involvement, while protection from enhanced PLCG2 function contradicts equating activation magnitude with harm; mechanistic mediation remains separate.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 57 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C58", "text": "Early ADAPT results found no prevention benefit from naproxen or celecoxib, with stopped treatment and unexpected prevalent cognitive disease at entry. Early imprecision and enrollment/treatment interruption limit interpretation; systemic NSAIDs do not selectively remove a defined glial state.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 58 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C59", "text": "ADAPT follow-up across approximately seven years found no overall AD incidence reduction after a median under 1.5 years of assigned NSAID treatment. Same randomized cohort as early ADAPT, not independent replication; delayed follow-up does not equal continuous long-term exposure or specific glial engagement.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 59 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C60", "text": "In 351 mild-to-moderate AD participants, one-year naproxen or rofecoxib did not slow the ADAS-Cog primary outcome or show consistent secondary benefit. COX inhibition and systemic adverse effects do not prove selective CNS mediator blockade; results constrain these doses and symptomatic-stage strategies.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 60 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C61", "text": "A 40-person randomized AD study found short-term MMSE improvement after three weeks of sargramostim, with peripheral immune and plasma biomarker changes. Safety-primary small study and brief cognitive effects do not establish sustained disease modification or a CNS glial mechanism; broader outcome and baseline details require original sections. Original Results and Methods: 40-person, three-week safety-primary trial. Baseline MMSE imbalance complicates the positive MMSE signal; baseline-adjusted end-of-treatment significance is lost, although the first follow-up remains positive. ADAS-Cog13 worsens at that follow-up, ADL/CDR-SB are null and the small PET subset is null. This is a mixed exploratory efficacy pattern, not established sustained benefit.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 61 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 2:RESULTS:paragraph11, 2:RESULTS:paragraph14, 2:RESULTS:paragraph16, 2:RESULTS:paragraph19, 2:RESULTS:paragraph23, 1:METHODS. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C62", "text": "MLKL ablation did not change SOD1 onset, progression, survival, neuron degeneration or glial activation despite prior necroptosis-pathway claims. This is a terminal-effector null in one familial model, not exclusion of every inflammatory pathway; expression-marker accumulation is insufficient mechanism evidence.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 62 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C63", "text": "Normal astrocyte-precursor transplantation in SOD1 rats reduced microgliosis, preserved motor neurons and respiratory/motor function and extended survival, partly through GLT1. Transplantation restores trophic/glutamate functions as well as inflammation; focal familial-model benefit does not isolate one harmful reactive state.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 63 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C64", "text": "AraC removal of proliferating CNS cells accelerated SOD1 progression while reducing microglia, progenitors and T cells. Multiple cell classes and anti-mitotic effects prevent attributing harm specifically to microglial loss, but contradict indiscriminate suppression as a universal strategy.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 64 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C65", "text": "RIPK3 silencing protected cultured neurons from SOD1 astrocytes, but genetic deletion did not improve mouse behavior or neuropathology. Culture rescue failed organismal follow-through for this mediator; it cannot be generalized as proof that all glial toxicity pathways are merely reactive.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 65 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C66", "text": "MyD88-deficient marrow transplantation advanced onset and shortened survival in SOD1-G37R mice relative to competent donor cells. Marrow conditioning and peripheral/engrafted myeloid contributions differ from native resident microglial activation; immune signaling was protective in this tested context.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 66 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C67", "text": "Combined IL1a, TNF and C1q knockout extended SOD1-G93A survival and interrogated the proposed microglia-to-reactive-astrocyte pathway. Global lifelong cytokine deletion is not astrocyte-specific loss; rescue, stage timing and alternative immune effects require body checks before attributing all benefit to one state. Original Results: lifelong global IL1α/TNF/C1q triple deletion delays motor-neuron loss and denervation rather than preventing eventual disease; mutant animals reach a later endpoint with similar loss. Disease onset remains similar. This is causal progression modification with a constitutive, systemic intervention.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 67 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph2, 1:Results:paragraph3, 1:Results:paragraph4, 1:Results:paragraph5, 1:Results:paragraph7. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C68", "text": "Microglial or T-cell depletion blocked tau-model degeneration, while IFNγ or PDCD1 inhibition ameliorated atrophy; human AD tissue contained expanded cytotoxic T cells. Adaptive and innate immune effects form a causal model hub downstream of tau, rather than proving all human activation is an initiating driver; linked correction remains attached. Original Results: peripheral T-cell depletion from 6 to 9.5 months reduces atrophy, NfL and functional deficits versus IgG controls; IFNγ blockade begins at 7.5 months and PLX3397 at 8.5 months. PLX3397 targets CSF1R, c-kit and FLT3. Tau burden also changes, and neither intervention isolates a glial-only mediator. Original results verify better Y-maze/auditory-cue performance and baseline locomotor controls; contextual freezing was only a trend.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 68 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 2:Interaction of microglia and T cells:paragraph2, 2:Interaction of microglia and T cells:paragraph3, 3:T cell depletion prevent degeneration:paragraph0, 3:T cell depletion prevent degeneration:paragraph1. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "C69", "text": "Trem2 deletion reduced microgliosis and preserved brain volume in PS19 despite similar phosphorylated/insoluble tau. This separates tau burden from immune-associated atrophy in a pure-tau background; amyloid and APOE4 experiments reverse or alter the direction, restricting generalization.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 69 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-06", "note": "" }, { "id": "CSC1", "text": "Presymptomatic animal changes and human preclinical/longitudinal observations exceed terminal colocalization alone. Human state ordering and direct neuronal-loss mediation remain unresolved; pseudotime and structural equation modeling do not identify an initiating event.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 1, 3, 9, 12, 24, 26, 28, 29, 32 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-06", "note": "" }, { "id": "CSC2", "text": "Endogenous cell-lineage perturbations of mutant SOD1, NFκB and astrocytic APOE, as well as complementary immune manipulations, materially alter survival, atrophy or function in specified models. Defined mediator causality crosses Δ and merits Ε with explicit genotype, state and timing restrictions. Protective SYK, TREM2, IL3 and innate signaling states rule out indiscriminate activation suppression.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21, 22, 23, 24, 25, 27, 28, 29, 30, 31, 33, 34, 35, 36, 38, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 62, 63, 64, 65, 66, 67, 68, 69 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-06", "note": "" }, { "id": "CSC3", "text": "Glial contributions exceed a passive bystander or clearance-only account. SOD1 removal in glia and partial NFκB suppression slow later progression without changing onset; these are reactive causal amplification, which qualifies under the registered wording. Astrocyte and microglial effects are not interchangeable and do not establish obligatory upstream initiation. This defined causal contribution is Ε.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21, 22, 23, 24, 25, 26, 27, 28, 30, 31, 33, 34, 36, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 62, 63, 64, 65, 66, 67, 68, 69 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-06", "note": "" }, { "id": "CSC4", "text": "AD, PD and ALS models show context-dependent causal immune effects, but human pathway engagement has not reliably produced sustained clinical benefit. AL002, NLY01, AZA-PD, ADAPT, NSAID treatment and minocycline test different, incompletely selective mechanisms. Protective and harmful states require prospective boundaries; the general disease-class claim remains Γ.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 1, 3, 20, 32, 35, 37, 38, 39, 40, 41, 42, 43, 44, 55, 56, 57, 58, 59, 60, 61 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-06", "note": "" }, { "id": "CH", "text": "Glial states can causally amplify degeneration, but harmful activation is not a general rule across disease, stage and human intervention.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 49, 48, 52, 67, 14, 40 ], "verification": "verified", "verified_against": "Bounded synthesis of examined sources; score is adjudication.", "verified_on": "2026-10-06", "note": "" } ], "citation_ledger": [ { "n": 1, "citation": "Smajić S, Prada-Medina CA, Landoulsi Z et al. Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state. Brain : a journal of neurology. 2022.", "tier": "A", "kind": "primary", "pmid": "34919646", "doi": "10.1093/brain/awab446", "url": "https://pubmed.ncbi.nlm.nih.gov/34919646/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID34919646", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C1", "CSC1", "CSC4" ] }, { "n": 2, "citation": "McAlpine CS, Park J, Griciuc A et al. Astrocytic interleukin-3 programs microglia and limits Alzheimer's disease. Nature. 2021.", "tier": "A", "kind": "primary", "pmid": "34262178", "doi": "10.1038/s41586-021-03734-6", "url": "https://pubmed.ncbi.nlm.nih.gov/34262178/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID34262178", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C2", "CSC2", "CSC3" ] }, { "n": 3, "citation": "Gabitto MI, Travaglini KJ, Rachleff VM et al. Integrated multimodal cell atlas of Alzheimer's disease. Nature neuroscience. 2024.", "tier": "A", "kind": "primary", "pmid": "39402379", "doi": "10.1038/s41593-024-01774-5", "url": "https://pubmed.ncbi.nlm.nih.gov/39402379/", "status_flags": [ "UpdateOf: PMID37292694" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID39402379", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C3", "CSC1", "CSC4" ] }, { "n": 4, "citation": "Yan YQ, Zheng R, Liu Y et al. Parkin regulates microglial NLRP3 and represses neurodegeneration in Parkinson's disease. Aging cell. 2023.", "tier": "A", "kind": "primary", "pmid": "37029500", "doi": "10.1111/acel.13834", "url": "https://pubmed.ncbi.nlm.nih.gov/37029500/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID37029500", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C4", "CSC2", "CSC3" ] }, { "n": 5, "citation": "Bido S, Nannoni M, Muggeo S et al. Microglia-specific IL-10 gene delivery inhibits neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease. Science translational medicine. 2024.", "tier": "A", "kind": "primary", "pmid": "39167665", "doi": "10.1126/scitranslmed.adm8563", "url": "https://pubmed.ncbi.nlm.nih.gov/39167665/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID39167665", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C5", "CSC2", "CSC3" ] }, { "n": 6, "citation": "Yun SP, Kam TI, Panicker N et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. Nature medicine. 2018.", "tier": "A", "kind": "primary", "pmid": "29892066", "doi": "10.1038/s41591-018-0051-5", "url": "https://pubmed.ncbi.nlm.nih.gov/29892066/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID29892066", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C6", "CSC2", "CSC3" ] }, { "n": 7, "citation": "Gordon R, Albornoz EA, Christie DC et al. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Science translational medicine. 2018.", "tier": "A", "kind": "primary", "pmid": "30381407", "doi": "10.1126/scitranslmed.aah4066", "url": "https://pubmed.ncbi.nlm.nih.gov/30381407/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID30381407", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C7", "CSC2", "CSC3" ] }, { "n": 8, "citation": "Dejanovic B, Wu T, Tsai MC et al. Complement C1q-dependent excitatory and inhibitory synapse elimination by astrocytes and microglia in Alzheimer's disease mouse models. Nature aging. 2022.", "tier": "A", "kind": "primary", "pmid": "37118504", "doi": "10.1038/s43587-022-00281-1", "url": "https://pubmed.ncbi.nlm.nih.gov/37118504/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID37118504", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C8", "CSC2", "CSC3" ] }, { "n": 9, "citation": "Qin L, Wu X, Block ML et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 2007.", "tier": "A", "kind": "primary", "pmid": "17203472", "doi": "10.1002/glia.20467", "url": "https://pubmed.ncbi.nlm.nih.gov/17203472/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID17203472", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C9", "CSC1", "CSC2", "CSC3" ] }, { "n": 10, "citation": "Tsunemi T, Ishiguro Y, Yoroisaka A et al. Astrocytes Protect Human Dopaminergic Neurons from α-Synuclein Accumulation and Propagation. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2020.", "tier": "A", "kind": "primary", "pmid": "33046546", "doi": "10.1523/JNEUROSCI.0954-20.2020", "url": "https://pubmed.ncbi.nlm.nih.gov/33046546/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID33046546", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C10", "CSC2", "CSC3" ] }, { "n": 11, "citation": "Castro-Sánchez S, García-Yagüe ÁJ, López-Royo T et al. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease. Glia. 2018.", "tier": "A", "kind": "primary", "pmid": "29624735", "doi": "10.1002/glia.23338", "url": "https://pubmed.ncbi.nlm.nih.gov/29624735/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID29624735", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C11", "CSC2", "CSC3" ] }, { "n": 12, "citation": "Hong S, Beja-Glasser VF, Nfonoyim BM et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science (New York, N.Y.). 2016.", "tier": "A", "kind": "primary", "pmid": "27033548", "doi": "10.1126/science.aad8373", "url": "https://pubmed.ncbi.nlm.nih.gov/27033548/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID27033548", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C12", "CSC1", "CSC2", "CSC3" ] }, { "n": 13, "citation": "Ulland TK, Song WM, Huang SC et al. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. Cell. 2017.", "tier": "A", "kind": "primary", "pmid": "28802038", "doi": "10.1016/j.cell.2017.07.023", "url": "https://pubmed.ncbi.nlm.nih.gov/28802038/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID28802038", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C13", "CSC2", "CSC3" ] }, { "n": 14, "citation": "Wang S, Sudan R, Peng V et al. TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways. Cell. 2022.", "tier": "A", "kind": "primary", "pmid": "36306735", "doi": "10.1016/j.cell.2022.09.033", "url": "https://pubmed.ncbi.nlm.nih.gov/36306735/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID36306735", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph0, 1:RESULTS:paragraph2, 1:RESULTS:paragraph3, 1:RESULTS:paragraph6, 1:RESULTS:paragraph14. No complete-paper or supplement audit claimed.", "carries_claims": [ "C14", "CSC2", "CSC3", "CH" ] }, { "n": 15, "citation": "Zhong L, Sheng X, Wang W et al. TREM2 receptor protects against complement-mediated synaptic loss by binding to complement C1q during neurodegeneration. Immunity. 2023.", "tier": "A", "kind": "primary", "pmid": "37442133", "doi": "10.1016/j.immuni.2023.06.016", "url": "https://pubmed.ncbi.nlm.nih.gov/37442133/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID37442133", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C15", "CSC2", "CSC3" ] }, { "n": 16, "citation": "Zhou J, Wade SD, Graykowski D et al. The neuronal pentraxin Nptx2 regulates complement activity and restrains microglia-mediated synapse loss in neurodegeneration. Science translational medicine. 2023.", "tier": "A", "kind": "primary", "pmid": "36989373", "doi": "10.1126/scitranslmed.adf0141", "url": "https://pubmed.ncbi.nlm.nih.gov/36989373/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID36989373", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C16", "CSC2", "CSC3" ] }, { "n": 17, "citation": "Wang Y, Cella M, Mallinson K et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell. 2015.", "tier": "A", "kind": "primary", "pmid": "25728668", "doi": "10.1016/j.cell.2015.01.049", "url": "https://pubmed.ncbi.nlm.nih.gov/25728668/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID25728668", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C17", "CSC2", "CSC3" ] }, { "n": 18, "citation": "Heckmann BL, Teubner BJW, Tummers B et al. LC3-Associated Endocytosis Facilitates β-Amyloid Clearance and Mitigates Neurodegeneration in Murine Alzheimer's Disease. Cell. 2019.", "tier": "A", "kind": "primary", "pmid": "31257024", "doi": "10.1016/j.cell.2019.05.056", "url": "https://pubmed.ncbi.nlm.nih.gov/31257024/", "status_flags": [ "ErratumIn: PMID33306957" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID31257024", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C18", "CSC2", "CSC3" ] }, { "n": 19, "citation": "Gratuze M, Leyns CE, Sauerbeck AD et al. Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration. The Journal of clinical investigation. 2020.", "tier": "A", "kind": "primary", "pmid": "32544086", "doi": "10.1172/JCI138179", "url": "https://pubmed.ncbi.nlm.nih.gov/32544086/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID32544086", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C19", "CSC2", "CSC3" ] }, { "n": 20, "citation": "Clarke N, Thornton P, Reader V et al. Anti-Neuroinflammatory and Anti-Inflammatory Effects of the NLRP3 Inhibitor NT-0796 in Subjects with Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society. 2025.", "tier": "A", "kind": "primary", "pmid": "40792655", "doi": "10.1002/mds.30307", "url": "https://pubmed.ncbi.nlm.nih.gov/40792655/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID40792655", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C20", "CSC4" ] }, { "n": 21, "citation": "Liang Y, Li S, Guo Q et al. Complement 3-deficient mice are not protected against MPTP-induced dopaminergic neurotoxicity. Brain research. 2007.", "tier": "A", "kind": "primary", "pmid": "17900537", "doi": "10.1016/j.brainres.2007.08.033", "url": "https://pubmed.ncbi.nlm.nih.gov/17900537/", "status_flags": [ "ErratumIn: PMID not supplied" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID17900537", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C21", "CSC2", "CSC3" ] }, { "n": 22, "citation": "Carpanini SM, Torvell M, Bevan RJ et al. Terminal complement pathway activation drives synaptic loss in Alzheimer's disease models. Acta neuropathologica communications. 2022.", "tier": "A", "kind": "primary", "pmid": "35794654", "doi": "10.1186/s40478-022-01404-w", "url": "https://pubmed.ncbi.nlm.nih.gov/35794654/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID35794654", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C22", "CSC2", "CSC3" ] }, { "n": 23, "citation": "Bido S, Muggeo S, Massimino L et al. Microglia-specific overexpression of α-synuclein leads to severe dopaminergic neurodegeneration by phagocytic exhaustion and oxidative toxicity. Nature communications. 2021.", "tier": "A", "kind": "primary", "pmid": "34716339", "doi": "10.1038/s41467-021-26519-x", "url": "https://pubmed.ncbi.nlm.nih.gov/34716339/", "status_flags": [ "ErratumIn: PMID34916524" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID34716339", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C23", "CSC2", "CSC3" ] }, { "n": 24, "citation": "Hinkle JT, Patel J, Panicker N et al. STING mediates neurodegeneration and neuroinflammation in nigrostriatal α-synucleinopathy. Proceedings of the National Academy of Sciences of the United States of America. 2022.", "tier": "A", "kind": "primary", "pmid": "35394877", "doi": "10.1073/pnas.2118819119", "url": "https://pubmed.ncbi.nlm.nih.gov/35394877/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID35394877", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C24", "CSC1", "CSC2", "CSC3" ] }, { "n": 25, "citation": "Wang C, Xiong M, Gratuze M et al. Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. Neuron. 2021.", "tier": "A", "kind": "primary", "pmid": "33831349", "doi": "10.1016/j.neuron.2021.03.024", "url": "https://pubmed.ncbi.nlm.nih.gov/33831349/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID33831349", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph0, 1:RESULTS:paragraph1, 1:RESULTS:paragraph2, 1:RESULTS:paragraph15. No complete-paper or supplement audit claimed.", "carries_claims": [ "C25", "CSC2", "CSC3" ] }, { "n": 26, "citation": "Gomez-Arboledas A, Davila JC, Sanchez-Mejias E et al. Phagocytic clearance of presynaptic dystrophies by reactive astrocytes in Alzheimer's disease. Glia. 2018.", "tier": "A", "kind": "primary", "pmid": "29178139", "doi": "10.1002/glia.23270", "url": "https://pubmed.ncbi.nlm.nih.gov/29178139/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID29178139", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C26", "CSC1", "CSC3" ] }, { "n": 27, "citation": "Han X, Li Q, Lan X et al. Microglial Depletion with Clodronate Liposomes Increases Proinflammatory Cytokine Levels, Induces Astrocyte Activation, and Damages Blood Vessel Integrity. Molecular neurobiology. 2019.", "tier": "A", "kind": "primary", "pmid": "30734229", "doi": "10.1007/s12035-019-1502-9", "url": "https://pubmed.ncbi.nlm.nih.gov/30734229/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID30734229", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C27", "CSC2", "CSC3" ] }, { "n": 28, "citation": "Liddelow SA, Guttenplan KA, Clarke LE et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017.", "tier": "A", "kind": "primary", "pmid": "28099414", "doi": "10.1038/nature21029", "url": "https://pubmed.ncbi.nlm.nih.gov/28099414/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID28099414", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C28", "CSC1", "CSC2", "CSC3" ] }, { "n": 29, "citation": "Keren-Shaul H, Spinrad A, Weiner A et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. Cell. 2017.", "tier": "A", "kind": "primary", "pmid": "28602351", "doi": "10.1016/j.cell.2017.05.018", "url": "https://pubmed.ncbi.nlm.nih.gov/28602351/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID28602351", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C29", "CSC1", "CSC2" ] }, { "n": 30, "citation": "Scheiblich H, Eikens F, Wischhof L et al. Microglia rescue neurons from aggregate-induced neuronal dysfunction and death through tunneling nanotubes. Neuron. 2024.", "tier": "A", "kind": "primary", "pmid": "39059388", "doi": "10.1016/j.neuron.2024.06.029", "url": "https://pubmed.ncbi.nlm.nih.gov/39059388/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID39059388", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C30", "CSC2", "CSC3" ] }, { "n": 31, "citation": "Ising C, Venegas C, Zhang S et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019.", "tier": "A", "kind": "primary", "pmid": "31748742", "doi": "10.1038/s41586-019-1769-z", "url": "https://pubmed.ncbi.nlm.nih.gov/31748742/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID31748742", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C31", "CSC2", "CSC3" ] }, { "n": 32, "citation": "Fernández-Matarrubia M, Valera-Barrero A, Renuncio-García M et al. Early microglial and astrocyte reactivity in preclinical Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025.", "tier": "A", "kind": "primary", "pmid": "40747577", "doi": "10.1002/alz.70502", "url": "https://pubmed.ncbi.nlm.nih.gov/40747577/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID40747577", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C32", "CSC1", "CSC4" ] }, { "n": 33, "citation": "Kummer MP, Ising C, Kummer C et al. Microglial PD-1 stimulation by astrocytic PD-L1 suppresses neuroinflammation and Alzheimer's disease pathology. The EMBO journal. 2021.", "tier": "A", "kind": "primary", "pmid": "34825707", "doi": "10.15252/embj.2021108662", "url": "https://pubmed.ncbi.nlm.nih.gov/34825707/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID34825707", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C33", "CSC2", "CSC3" ] }, { "n": 34, "citation": "Venegas C, Kumar S, Franklin BS et al. Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer's disease. Nature. 2017.", "tier": "A", "kind": "primary", "pmid": "29293211", "doi": "10.1038/nature25158", "url": "https://pubmed.ncbi.nlm.nih.gov/29293211/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID29293211", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C34", "CSC2", "CSC3" ] }, { "n": 35, "citation": "Wang S, Mustafa M, Yuede CM et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model. The Journal of experimental medicine. 2020.", "tier": "A", "kind": "primary", "pmid": "32579671", "doi": "10.1084/jem.20200785", "url": "https://pubmed.ncbi.nlm.nih.gov/32579671/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID32579671", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C35", "CSC2", "CSC4" ] }, { "n": 36, "citation": "Gratuze M, Schlachetzki JCM, D'Oliveira Albanus R et al. TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4. Neuron. 2023.", "tier": "A", "kind": "primary", "pmid": "36368315", "doi": "10.1016/j.neuron.2022.10.022", "url": "https://pubmed.ncbi.nlm.nih.gov/36368315/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID36368315", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C36", "CSC2", "CSC3" ] }, { "n": 37, "citation": "Long H, Simmons A, Mayorga A et al. Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease. Alzheimer's research & therapy. 2024.", "tier": "A", "kind": "rct", "pmid": "39444037", "doi": "10.1186/s13195-024-01599-1", "url": "https://pubmed.ncbi.nlm.nih.gov/39444037/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID39444037", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C37", "CSC4" ] }, { "n": 38, "citation": "Takalo M, Wittrahm R, Wefers B et al. The Alzheimer's disease-associated protective Plcγ2-P522R variant promotes immune functions. Molecular neurodegeneration. 2020.", "tier": "A", "kind": "primary", "pmid": "32917267", "doi": "10.1186/s13024-020-00402-7", "url": "https://pubmed.ncbi.nlm.nih.gov/32917267/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID32917267", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C38", "CSC2", "CSC4" ] }, { "n": 39, "citation": "Gordon PH, Moore DH, Miller RG et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. The Lancet. Neurology. 2007.", "tier": "A", "kind": "rct", "pmid": "17980667", "doi": "10.1016/S1474-4422(07)70270-3", "url": "https://pubmed.ncbi.nlm.nih.gov/17980667/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID17980667", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C39", "CSC4" ] }, { "n": 40, "citation": "Mummery CJ, Mayorga AJ, Simmons A et al. The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial. Nature medicine. 2026.", "tier": "A", "kind": "rct", "pmid": "41787076", "doi": "10.1038/s41591-026-04273-1", "url": "https://pubmed.ncbi.nlm.nih.gov/41787076/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID41787076", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C40", "CSC4", "CH" ] }, { "n": 41, "citation": "Cummings JL, Atri A, Sano M et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet (London, England). 2026.", "tier": "A", "kind": "rct", "pmid": "41865758", "doi": "10.1016/S0140-6736(26)00459-9", "url": "https://pubmed.ncbi.nlm.nih.gov/41865758/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "EVOKE-and-EVOKEplus-two-trials-one-report", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C41", "CSC4" ] }, { "n": 42, "citation": "McGarry A, Rosanbalm S, Leinonen M et al. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial. The Lancet. Neurology. 2024.", "tier": "A", "kind": "rct", "pmid": "38101901", "doi": "10.1016/S1474-4422(23)00378-2", "url": "https://pubmed.ncbi.nlm.nih.gov/38101901/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID38101901", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C42", "CSC4" ] }, { "n": 43, "citation": "Greenland JC, Dresser K, Cutting E et al. Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. The Lancet. Neurology. 2026.", "tier": "A", "kind": "rct", "pmid": "41389828", "doi": "10.1016/S1474-4422(25)00386-2", "url": "https://pubmed.ncbi.nlm.nih.gov/41389828/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID41389828", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C43", "CSC4" ] }, { "n": 44, "citation": "Gendelman HE, Zhang Y, Santamaria P et al. Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial. NPJ Parkinson's disease. 2017.", "tier": "A", "kind": "primary", "pmid": "28649610", "doi": "10.1038/s41531-017-0013-5", "url": "https://pubmed.ncbi.nlm.nih.gov/28649610/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID28649610", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C44", "CSC4" ] }, { "n": 45, "citation": "Brenner D, Sieverding K, Bruno C et al. Heterozygous Tbk1 loss has opposing effects in early and late stages of ALS in mice. The Journal of experimental medicine. 2019.", "tier": "A", "kind": "primary", "pmid": "30635357", "doi": "10.1084/jem.20180729", "url": "https://pubmed.ncbi.nlm.nih.gov/30635357/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID30635357", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C45", "CSC2", "CSC3" ] }, { "n": 46, "citation": "Mesci P, Zaïdi S, Lobsiger CS et al. System xC- is a mediator of microglial function and its deletion slows symptoms in amyotrophic lateral sclerosis mice. Brain : a journal of neurology. 2015.", "tier": "A", "kind": "primary", "pmid": "25384799", "doi": "10.1093/brain/awu312", "url": "https://pubmed.ncbi.nlm.nih.gov/25384799/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID25384799", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C46", "CSC2", "CSC3" ] }, { "n": 47, "citation": "Lobsiger CS, Boillée S, Pozniak C et al. C1q induction and global complement pathway activation do not contribute to ALS toxicity in mutant SOD1 mice. Proceedings of the National Academy of Sciences of the United States of America. 2013.", "tier": "A", "kind": "primary", "pmid": "24170856", "doi": "10.1073/pnas.1318309110", "url": "https://pubmed.ncbi.nlm.nih.gov/24170856/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID24170856", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C47", "CSC2", "CSC3" ] }, { "n": 48, "citation": "Yamanaka K, Chun SJ, Boillee S et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nature neuroscience. 2008.", "tier": "A", "kind": "primary", "pmid": "18246065", "doi": "10.1038/nn2047", "url": "https://pubmed.ncbi.nlm.nih.gov/18246065/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID18246065", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C48", "CSC2", "CSC3", "CH" ] }, { "n": 49, "citation": "Boillée S, Yamanaka K, Lobsiger CS et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science (New York, N.Y.). 2006.", "tier": "A", "kind": "primary", "pmid": "16741123", "doi": "10.1126/science.1123511", "url": "https://pubmed.ncbi.nlm.nih.gov/16741123/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID16741123", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C49", "CSC2", "CSC3", "CH" ] }, { "n": 50, "citation": "Endo F, Komine O, Fujimori-Tonou N et al. Astrocyte-derived TGF-β1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells. Cell reports. 2015.", "tier": "A", "kind": "primary", "pmid": "25892237", "doi": "10.1016/j.celrep.2015.03.053", "url": "https://pubmed.ncbi.nlm.nih.gov/25892237/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID25892237", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C50", "CSC2", "CSC3" ] }, { "n": 51, "citation": "Komine O, Yamashita H, Fujimori-Tonou N et al. Innate immune adaptor TRIF deficiency accelerates disease progression of ALS mice with accumulation of aberrantly activated astrocytes. Cell death and differentiation. 2018.", "tier": "A", "kind": "primary", "pmid": "29568058", "doi": "10.1038/s41418-018-0098-3", "url": "https://pubmed.ncbi.nlm.nih.gov/29568058/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID29568058", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C51", "CSC2", "CSC3" ] }, { "n": 52, "citation": "Frakes AE, Ferraiuolo L, Haidet-Phillips AM et al. Microglia induce motor neuron death via the classical NF-κB pathway in amyotrophic lateral sclerosis. Neuron. 2014.", "tier": "A", "kind": "primary", "pmid": "24607225", "doi": "10.1016/j.neuron.2014.01.013", "url": "https://pubmed.ncbi.nlm.nih.gov/24607225/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID24607225", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph8, 1:RESULTS:paragraph9, 1:RESULTS:paragraph12, 1:RESULTS:paragraph13. No complete-paper or supplement audit claimed.", "carries_claims": [ "C52", "CSC2", "CSC3", "CH" ] }, { "n": 53, "citation": "Heneka MT, Kummer MP, Stutz A et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 2013.", "tier": "A", "kind": "primary", "pmid": "23254930", "doi": "10.1038/nature11729", "url": "https://pubmed.ncbi.nlm.nih.gov/23254930/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID23254930", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C53", "CSC2", "CSC3" ] }, { "n": 54, "citation": "Spangenberg EE, Lee RJ, Najafi AR et al. Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-β pathology. Brain : a journal of neurology. 2016.", "tier": "A", "kind": "primary", "pmid": "26921617", "doi": "10.1093/brain/aww016", "url": "https://pubmed.ncbi.nlm.nih.gov/26921617/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID26921617", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C54", "CSC2", "CSC3" ] }, { "n": 55, "citation": "Guerreiro R, Wojtas A, Bras J et al. TREM2 variants in Alzheimer's disease. The New England journal of medicine. 2013.", "tier": "A", "kind": "primary", "pmid": "23150934", "doi": "10.1056/NEJMoa1211851", "url": "https://pubmed.ncbi.nlm.nih.gov/23150934/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID23150934", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C55", "CSC4" ] }, { "n": 56, "citation": "Jonsson T, Stefansson H, Steinberg S et al. Variant of TREM2 associated with the risk of Alzheimer's disease. The New England journal of medicine. 2013.", "tier": "A", "kind": "primary", "pmid": "23150908", "doi": "10.1056/NEJMoa1211103", "url": "https://pubmed.ncbi.nlm.nih.gov/23150908/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID23150908", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C56", "CSC4" ] }, { "n": 57, "citation": "Sims R, van der Lee SJ, Naj AC et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature genetics. 2017.", "tier": "A", "kind": "primary", "pmid": "28714976", "doi": "10.1038/ng.3916", "url": "https://pubmed.ncbi.nlm.nih.gov/28714976/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID28714976", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C57", "CSC4" ] }, { "n": 58, "citation": "ADAPT Research Group, Lyketsos CG, Breitner JC et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007.", "tier": "A", "kind": "rct", "pmid": "17460158", "doi": "10.1212/01.wnl.0000260269.93245.d2", "url": "https://pubmed.ncbi.nlm.nih.gov/17460158/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "ADAPT-original-randomization", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C58", "CSC4" ] }, { "n": 59, "citation": "Alzheimer's Disease Anti-inflammatory Prevention Trial Research Group. Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimer's & dementia : the journal of the Alzheimer's Association. 2013.", "tier": "A", "kind": "rct", "pmid": "23562431", "doi": "10.1016/j.jalz.2012.11.012", "url": "https://pubmed.ncbi.nlm.nih.gov/23562431/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "ADAPT-original-randomization", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C59", "CSC4" ] }, { "n": 60, "citation": "Aisen PS, Schafer KA, Grundman M et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003.", "tier": "A", "kind": "rct", "pmid": "12783912", "doi": "10.1001/jama.289.21.2819", "url": "https://pubmed.ncbi.nlm.nih.gov/12783912/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID12783912", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C60", "CSC4" ] }, { "n": 61, "citation": "Potter H, Woodcock JH, Boyd TD et al. Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer's disease. Alzheimer's & dementia (New York, N. Y.). 2021.", "tier": "A", "kind": "primary", "pmid": "33778150", "doi": "10.1002/trc2.12158", "url": "https://pubmed.ncbi.nlm.nih.gov/33778150/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID33778150", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 2:RESULTS:paragraph11, 2:RESULTS:paragraph14, 2:RESULTS:paragraph16, 2:RESULTS:paragraph19, 2:RESULTS:paragraph23, 1:METHODS. No complete-paper or supplement audit claimed.", "carries_claims": [ "C61", "CSC4" ] }, { "n": 62, "citation": "Wang T, Perera ND, Chiam MDF et al. Necroptosis is dispensable for motor neuron degeneration in a mouse model of ALS. Cell death and differentiation. 2020.", "tier": "A", "kind": "primary", "pmid": "31745214", "doi": "10.1038/s41418-019-0457-8", "url": "https://pubmed.ncbi.nlm.nih.gov/31745214/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID31745214", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C62", "CSC2", "CSC3" ] }, { "n": 63, "citation": "Lepore AC, Rauck B, Dejea C et al. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nature neuroscience. 2008.", "tier": "A", "kind": "primary", "pmid": "18931666", "doi": "10.1038/nn.2210", "url": "https://pubmed.ncbi.nlm.nih.gov/18931666/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID18931666", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C63", "CSC2", "CSC3" ] }, { "n": 64, "citation": "Audet JN, Gowing G, Paradis R et al. Ablation of proliferating cells in the CNS exacerbates motor neuron disease caused by mutant superoxide dismutase. PloS one. 2012.", "tier": "A", "kind": "primary", "pmid": "22523565", "doi": "10.1371/journal.pone.0034932", "url": "https://pubmed.ncbi.nlm.nih.gov/22523565/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID22523565", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C64", "CSC2", "CSC3" ] }, { "n": 65, "citation": "Dermentzaki G, Politi KA, Lu L et al. Deletion of Ripk3 Prevents Motor Neuron Death In Vitro but not In Vivo. eNeuro. 2019.", "tier": "A", "kind": "primary", "pmid": "30815534", "doi": "10.1523/ENEURO.0308-18.2018", "url": "https://pubmed.ncbi.nlm.nih.gov/30815534/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID30815534", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C65", "CSC2", "CSC3" ] }, { "n": 66, "citation": "Kang J, Rivest S et al. MyD88-deficient bone marrow cells accelerate onset and reduce survival in a mouse model of amyotrophic lateral sclerosis. The Journal of cell biology. 2007.", "tier": "A", "kind": "primary", "pmid": "18086918", "doi": "10.1083/jcb.200705046", "url": "https://pubmed.ncbi.nlm.nih.gov/18086918/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID18086918", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C66", "CSC2", "CSC3" ] }, { "n": 67, "citation": "Guttenplan KA, Weigel MK, Adler DI et al. Knockout of reactive astrocyte activating factors slows disease progression in an ALS mouse model. Nature communications. 2020.", "tier": "A", "kind": "primary", "pmid": "32719333", "doi": "10.1038/s41467-020-17514-9", "url": "https://pubmed.ncbi.nlm.nih.gov/32719333/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID32719333", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph2, 1:Results:paragraph3, 1:Results:paragraph4, 1:Results:paragraph5, 1:Results:paragraph7. No complete-paper or supplement audit claimed.", "carries_claims": [ "C67", "CSC2", "CSC3", "CH" ] }, { "n": 68, "citation": "Chen X, Firulyova M, Manis M et al. Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy. Nature. 2023.", "tier": "A", "kind": "primary", "pmid": "36890231", "doi": "10.1038/s41586-023-05788-0", "url": "https://pubmed.ncbi.nlm.nih.gov/36890231/", "status_flags": [ "ErratumIn: PMID39415023" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID36890231", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 2:Interaction of microglia and T cells:paragraph2, 2:Interaction of microglia and T cells:paragraph3, 3:T cell depletion prevent degeneration:paragraph0, 3:T cell depletion prevent degeneration:paragraph1. No complete-paper or supplement audit claimed.", "carries_claims": [ "C68", "CSC2", "CSC3" ] }, { "n": 69, "citation": "Leyns CEG, Ulrich JD, Finn MB et al. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proceedings of the National Academy of Sciences of the United States of America. 2017.", "tier": "A", "kind": "primary", "pmid": "29073081", "doi": "10.1073/pnas.1710311114", "url": "https://pubmed.ncbi.nlm.nih.gov/29073081/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-06", "status_checked_on": "2026-10-06", "study_id": "PMID29073081", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C69", "CSC2", "CSC3" ] } ], "independence_basis": { "required": false, "lines": [ { "label": "Cell-lineage and timing perturbations", "sources": [ 49, 48, 52, 25 ], "excludes_error": "Exclude a wholly passive glial role in defined models; shared proteinopathy backgrounds and pleiotropy remain." }, { "label": "Protective-state loss and rescue", "sources": [ 14, 2, 51 ], "excludes_error": "Exclude indiscriminate harmful activation and expose clearance/state dependence." }, { "label": "Adaptive immune hub perturbations", "sources": [ 68, 5 ], "excludes_error": "Exclude a solely neuron-autonomous progression account, while retaining peripheral and aggregate-burden mediation." }, { "label": "Randomized human interventions", "sources": [ 40, 42, 43, 39, 60, 61 ], "excludes_error": "Narrow treatment confounding but do not universally verify cell-state engagement; null, harmful and mixed results are retained." }, { "label": "Human risk genetics", "sources": [ 55, 56, 57 ], "excludes_error": "Support immune relevance, but risk alleles do not identify a single inflammatory mediator or prove suppression should help." } ], "shared_failure_mode_checked": true, "note": "The 69 reports are not 69 independent causal lines. ADAPT follow-up reuses the original randomization. Several SOD1, P301S/APOE and 5xFAD studies share engineered backgrounds and laboratories. Genetic cohorts can overlap. Orthogonal timing, cell-lineage, protection and clinical endpoint contrasts cover different weaknesses, but none yet settles the broad human state-specific claim." }, "consensus_validation": { "completed": true, "status": "documented_historical_discovery_and_reconciliation", "provider": "Consensus", "provider_mode": "Historical browser/connector use as recorded in the source artifacts", "local_audit_date": "2026-10-09", "primary_comparison_count": null, "reported_usage": [], "grade_changed": false, "score_before": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "69 primary reports with 6 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.", "rests_on_non_peer_reviewed_work": false, "rationale": "The registered weakest-link conjunction returns Γ because disease-class human generalization remains unresolved. Defined glial states have real causal effects on neuronal loss and progression, including reactive amplifiers. This evidence is not dismissed for being downstream. Opposite effects of protective immune programs and negative or harmful human interventions prevent treating chronic activation as one broadly pathogenic exposure. The limiting gate is generalization and state-specific human mediation, not an added obligation to initiate disease." }, "score_after": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "69 primary reports with 6 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.", "rests_on_non_peer_reviewed_work": false, "rationale": "The registered weakest-link conjunction returns Γ because disease-class human generalization remains unresolved. Defined glial states have real causal effects on neuronal loss and progression, including reactive amplifiers. This evidence is not dismissed for being downstream. Opposite effects of protective immune programs and negative or harmful human interventions prevent treating chronic activation as one broadly pathogenic exposure. The limiting gate is generalization and state-specific human mediation, not an added obligation to initiate disease." }, "independent_blinded_audit": false, "raw_receipts": [ { "path": "deliverables\\hsef_v53_popularity_ranks_21_25_2026-10-06\\neuroinflammation-ranked-refresh\\consensus\\broad-browser-snapshot.txt", "sha256": "a6fe2688372703af971bd35ce5aa7b59e66171cceb05215d5ddc4251481dd0ff" }, { "path": "deliverables\\hsef_v53_popularity_ranks_21_25_2026-10-06\\neuroinflammation-ranked-refresh\\consensus\\query-ledger.json", "sha256": "6f48a021f249a5f2d15e4d7eb04bcf45c5e38e56d80dc5c9b8c15bdb5dbfa240" }, { "path": "deliverables\\hsef_v53_popularity_ranks_21_25_2026-10-06\\neuroinflammation-ranked-refresh\\consensus\\reconciliation.md", "sha256": "b3a7ea6a5c74184bab9f6ccc5e5bce46fb22c8a82a380644af02f4579157ebb6" }, { "path": "deliverables\\hsef_v53_popularity_ranks_21_25_2026-10-06\\neuroinflammation-ranked-refresh\\consensus\\targeted-browser-snapshot.txt", "sha256": "0ebe1836b56e09d1986def71edc5697bf12e7cc0bb5b76b590ef0a424a5412f4" } ], "limitations": "This verifies documented historical use and links the record to the final edition. It adds no primary-source, full-text, independence or verification credit. Original access remains limited to the source-specific record." } }